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ABSTRACT 
Ochratoxin A (OTA), a nephrotoxic mycotoxin, is a contaminant of several agricultural food 
products consumed by animals and humans. Apart from renal toxicity, in particular renal 
tumours, OT A may also result in teratogenicity, neurotoxicity and immunotoxicity. 
Sutherlandia frutescens, an indigenous medicinal plant, has shown significant potential in 
strengthening the immune system and in cancer treatment, with minimal side effects. The 
objective of this study was to determine the effects of OT A in male Wistar rats and ascertain 
if these effects may be reduced by S. frutescens. 
Rats were treated by intraperitoneal injection (i.p) with either a control (EtOH:dH20;30:70), 
S. frutescens (l.Omg/kg body weight), OTA (O.5mg/kg body weight) or a combination of 
OT A and S. frutescens for a period of 1 or 7 days (n=4). Genotoxicity and metabolic activity 
in peripheral blood mononuclear cells (PBMCs) were quantified using single cell gel 
electrophoresis (SCGE) and the methylthiazol tetrazolium (MTT) assay, respectively. 
Lymphocyte apoptosis and mitochondrial depolarisation were measured by flow cytometry. 
Fluorescence microscopy was utilised to determine renal tissue apoptosis (Hoechst staining) 
and OTA localisation using immunohistochemistry (IRC). SDS-PAGE and Western blot 
were utilised to determine protein expression in kidney tissue and serum. 
Ochratoxin A significantly reduced PBMC viability (14%) after 7 days, compared with Day I 
(p<O.OOI). Lymphocyte mitochondrial depolarisation was 56.5% and 66.2% in the OTA-only 
and combination groups, respectively after 7 days (p<O.OOl). Ochratoxin A produced an 
increase in DNA damage compared to the control (p<O.OI). The renal tissue displayed typical 
signs of apoptosis such as chromatin condensation. Ochratoxin A was immunolocalised 
within the glomerulus. The protein analysis showed a decreased expression in the kidney 
mitochondrial protein fraction. Ochratoxin A preferentially bound to serum albumin and a 
120kDa protein in the OTA-only and co-treatment groups after the I-and 7-day regimes. 
Protein band intensities significantly decreased after the 7-day co-treatment (p<O.OI). 
The data highlights that OT A toxicity IS mediated by mitochondrial dysfunction. 
Furthermore, OT A disI1lptions in immune function may playa role in renal damage. 
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Diseases of the kidney and urinary tract together account for approximately 830 000 deaths 
annually, ranking them 12th among the causes of deaths worldwide (Disease Control Priorities 
Project, 2008). Furthermore, approximately 2 to 3% of medical admissions in Africa are due 
to renal-related complaints and it is believed that kidney disease is more prevalent and severe 
in Africa than in Western countries. The kidneys receive 25% of cardiac output and are 
therefore susceptible to toxicity and disease. 
The kidneys become vulnerable to injury due to the high metabolic activity of renal tubular 
cells. Also, glomerular filtrate concentration and active cell transport may result in renal 
tubular cells being exposed to higher concentrations of toxicants than are the cells of other 
organs. Subsequent disruptions could ultimately result in renal injury or failure. These 
disruptions may often be the result of dietary mycotoxins. Mycotoxins are toxins produced by 
various moulds that commonly infect agricultural commodities. When the humidity and 
temperature conditions are sufficient, there is fungal proliferation and thus an increase in 
mycotoxin production. There is a growing global concern regarding the impact of 
mycotoxins on the environment and the resultant economic losses. 
Ochratoxin A (OT A), a mycotoxin produced by the fungi Aspergillus and Penicillium species, 
is found in several agricultural food products owing to their often improper storage. The 
presence of OT A in food products such as coffee, wine, beer, grape juice, meat and meat 
products is possible because of its chemical stability during industrial processing (AI-Anati 
and Petzinger, 2006). The kidney is the target organ of OT A toxicity and chronic exposure 
results in the formation of renal tumours. Apart from renal toxicity, OT A also promotes 
teratogenicity, immunotoxicity and even neurotoxicity. The International Agency for 
Research on Cancer (IARC) has classified OT A as a group 2B carcinogen, possibly 
carcinogenic to humans (IARC, 1993). The proposed mechanisms by which OTA disrupts 
cell homeostasis include DNA damage, protein synthesis inhibition, apoptosis and oxidative 
stress (Ringot et al., 2006; Marin-Kuan et al. , 2008). Mitochondria are significant in the 
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induction of apoptosis since mitochondria receive signals to induce apoptosis. It is believed 
that mitochondria may playa significant role in the early toxicity of OT A (AI eo et ai., 1991). 
Furthennore, OT A toxicity may also exaggerate the effects of other diseases. 
Complementary medicine is a rapidly growing field and is gaining exposure in modem 
healthcare. It is believed that 80% of Africans rely on herbal medication and traditional 
health care for the treatment of various ailments (Ojewole, 2008). Medicinal plants are often 
thought to be safer than conventional medication, having minimal side effects. The medicinal 
plant SutheriandiaJrutescens, also commonly known as 'cancer bush', is known for its many 
diverse uses; it is used, for example, in the treatment of cancer, diabetes, influenza, 
tuberculosis and anxiety (van Wyk and Albrecht, 2008). Some of the active ingredients found 
in this plant include L-canavanine, y-aminobutyric acid (GABA), D-pinitol, L-arginine, 
flavonoids and triterpenoid saponins. The leaves of the plant are used in the production of the 
commercial tablets. 
Sutheriandia Jrutescens is currently being used in South Africa for the treatment of 
HIV / AIDS. The active ingredients in this plant may have positive effects on the immune 
system of patients. A safety study, conducted by the Medical Research Council of South 
Africa, showed that S. Jrutescens, at the recommended dose (9mglkg) and higher, was 
non-toxic and safe (Seier et ai., 2002). The minimal side effects of S. Jrutescens treatment 
make this plant safe to use and it is also relatively affordable. It is important to realise that 
individuals with a lower income are often unable to access the necessary treatment. If 
treatment is unavailable, then these individuals are at a higher risk of suffering from disease. 
Considering that S. Jrutescens is cost-effective and has various uses, this medicinal plant was 
used in the present study to detennine any cyto-protection against OT A toxicity. 
Ochratoxin A poses a serious threat to human and animal health as it is present in many 
agricultural food products. The eradication of OT A is difficult owing to its chemical and heat 
stability. Attention needs, therefore, to be focussed on minimising OT A-induced toxicity. 
Appropriate biochemical assays may prove to be beneficial in disease reduction. 
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The following aims were investigated in male Wistar rats: 
• To determine the effect of OT A immunotoxicity, by evaluating metabolic activity and 
apoptosis in peripheral blood mononuclear cells; 
• To identify the genotoxic potential of OTA; 
• To investigate the biochemical and morphological features of OTA-associated renal 
toxicity; 
• To ascertain the cyto-protective properties of S. frutescens against OT A toxicity. 
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CHAPTER 2 
LITERA TURE REVIEW 
Ochratoxin A (OT A), a mycotoxin, IS a secondary metabolite of the fungal species 
Aspergillus and Penicillium (Koller et ai. , 2006). The most important fungi to produce OT A 
are Aspergillus ochraceus and Penicillium verrucosum. Production of OT A occurs as a result 
of improper storage conditions, such as high moisture, which results in an excessive 
proliferation of fungi . The chemical structure of OT A is represented by a polyketide-derived 
dihydroisocoumarin moiety linked through the 12-carboxy group to L-phenylalanine at 
carbon 9 (Ringot et at., 2006) (Fig. 2.1). 
OH 0 
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Figure 2.1: Structure of Ochratoxin A (Hassen et ai., 2007). 
The phenolic group on the dihydroisocoumarin may be involved in the toxicity of OT A. The 
higher acidity of the phenolic group may be due to the aromatic ring that tightly couples with 
oxygen and is relatively loose between oxygen and hydrogen. De-protonation of the phenol 
group of the dihydroisocoumarin fOTITIS a phenolate ion and this may be related to either the 
absorption, elimination or binding of OT A to proteins (Dais et at. , 2005). Ochratoxin A is a 
colourless crystalline compound that fluoresces blue under ultraviolet (UV) light. 
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Ochratoxin A is commonly found in cereals, beer, wine, coffee, nuts, fruit juice and spices 
that have not been properly stored (Petzinger and Ziegler, 2000). Humans may be exposed to 
OT A after ingesting contaminated food or drink. Toxicity may also occur in animals, which 
may in turn lead to the contamination of meat and milk products. 
2.1 MECHANISMS OF TOXICITY 
There are certain mechanisms that occur in a cell which make a compound toxic. The initial 
step is the delivery of the toxin from the site of exposure to the target site. With regard to 
this, the compound that causes toxicity may be the parent compound, a metabolite or a 
reactive oxygen or reactive nitrogen species (Ringot et ai., 2006). Secondly, the toxic 
compound may react to a target molecule. This is not, however, always the case, as some 
xenobiotics may alter the biological environment, leading to a toxic response. Toxicity may 
also occur if there are changes in cellular signalling. Toxicity can further be induced if the 
cell ' s repair mechanisms are disturbed. 
Toxicokinetics and toxicodynamics are both important in OT A toxicity. Toxicokinetics refers 
to the change in concentration of a compound in the organism after a certain period of time 
(Ringot et ai. , 2006). Toxicodynamics refers to the interaction of a compound with its 
biological targets and their subsequent downstream biological effects (Ringot et ai., 2006). 
Another factor that could affect toxicity is bioavailabilty, which is the amount of a particular 
toxin that reaches the systemic circulation (Marquardt and Frohlich, 1992). The distribution 
pattern of OT A in pigs, rats, chickens and goats is believed to be in the following descending 
order: kidney, liver, muscle, fat and/or kidney, muscle, liver and fat (Ringot et ai., 2006). 
After oral administration to mammals, OT A may reach the systemic circulation without any 
chemical modification, which means that its bioavailability remains high (Marquardt and 
Frohlich, 1992; Li et ai., 1997). 
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2.2 ROUTE OF TOXIN EXPOSURE 
It has been established that when animals are given oral doses of OT A as compared with an 
intravenous injection (i.v), the half-life of OTA is low (Petzinger and Ziegler, 2000). 
Intraperitoneal injection (i.p) was chosen for the present study. This serves as a valuable tool 
in helping to clarify the mechanism of action of mycotoxins (Bondy et ai., 1995). Using the 
i.p route, the toxin is injected into the peritoneal cavity. According to Coria-Avila et at. 
(2007), substances deposited into the peritoneal cavity in rats are absorbed by vessels such as 
the colic and the intestinal and mesenteric veins, which converge into the anterior mesenteric 
vein. Blood is subsequently carried to the liver. After being metabolised in the liver, the i.p 
injected substances are taken to the heart, lungs and, thereafter, into the circulatory system 
(Coria-Avila et ai., 2007). It is believed that despite this long process, the speed of absorption 
is 25 - 50% the speed of i.v injections. Also, this route eliminates the possible cleavage of the 
toxin in the digestive tract (Maaroufi et at. , 1999). 
2.3 BIOTRANSFORMATION OF OCHRATOXIN A 
The hydrolysis of OT A results in the formation of a less toxic compound, referred to as 
OT A-a (O'Brien and Dietrich, 2005). This is formed by the cleavage of the peptide bond by 
peptidases, such as carboxypeptidase A or acid hydrolysis (Zepnik et at., 2003). It is believed 
that OT A metabolism is catalysed by cytochrome P450 (CYP450) enzymes, which leads to 
the production of 4-hydroxyochratoxin A (4R-OH-OTA) and 4S-0H-OTA (Marquardt and 
Frohlich, 1992; O'Brien and Dietrich, 2005; Ringot et ai., 2006). These intermediates are less 
toxic than the parent compound (OT A) and may have a shorter half-life (Li et ai., 1997). 
Simarro Doorten et at. (2004) found that CYP450-dependent OTA metabolism results in less 
toxic intermediates than does CYP2C9-dependent metabolism. It has also been suggested that 
OT A quinones may be formed by an iron-porphyrin complex (Gillman et at., 1999). 
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2.4 EFFECT OF oeHRA TOXIN A IN THE BODY 
In the body, OT A may accumulate in the liver, blood and kidney (Schwerdt et ai. , 1996; 
Maaroufi et ai. , 1999; Zepnik et ai. , 2003 ; Ringot et ai., 2006). The toxic properties of OT A 
include DNA damage, nephrotoxicity, immunotoxicity and carcinogenicity. Ochratoxin A 
nephrotoxicity may occur as a result of mitochondrial respiration inhibition and lipid 
peroxidation (Simon et ai., 1996). Cell damage by oxidative stress was enhanced when 
kidney and liver cells were treated with OT A and the production of reactive oxygen species 
(ROS) in the presence of OTA increased in a time- and dose-dependent manner (Gautier et 
ai. , 2001 b; Schaaf et ai., 2002; Boesch-Saadatmandi et ai. , 2008). Furthermore, calcium 
homeostasis, inhibition of protein synthesis and signalling pathways are also disrupted, which 
can eventually lead to carcinogenesis (Simon et ai., 1996; Marin-Kuan et ai., 2006). The 
half-life of OTA in humans exceeds 800 hours (Kamp et ai., 2005) and in rats is between 
55 and 120 hours (O'Brien and Dietrich, 2005). 
Low concentrations of OT A can alter cell homeostasis as it disturbs the cellular pH balance 
and influences the cellular calcium balance (Schwerdt et ai., 2004; Webber et ai., 2005). 
Cellular pH may determine cell proliferation. Also, medium to high doses of OT A may be 
associated with high incidences of metastasis (Mally and Dekant, 2005). 
The pH level of ingested food may also be important for OT A absorption. Both the 
monoanion (OTA) and dianion (OTA2-) forms of OTA are present at physiological pH 
conditions of the duodenal chyme (Ringot et ai., 2006). The fully protonated form is mainly 
present in acid solutions, such as the upper parts of the gastrointestinal tract (Ringot et ai. , 
2006). 
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2.5 TARGET ORGAN OF TOXICITY - THE KIDNEY 
Several factors detennine the susceptibility of a target organ to toxicity. These factors include 
the phannacokinetics of the compound, the metabolic fate of the compound and the target 
organs ability to respond to toxicity (Pfaller and Gstraunthaler, 1998). The kidney is the 
target organ of OT A toxicity. Typical features associated with OTA-induced renal toxicity 
are: single cell death, karyomegaly, polyploidy, frequent mitosis and kidney tubular cell 
degeneration and tubule disorganisation (Maaroufi et al. , 1999; Aydin et al., 2003; Schwerdt 
et ai. , 2007). 
The morphological characteristics and tumours observed in the kidneys of patients diagnosed 
with Balkan Endemic Nephropathy (BEN) are similar to those of patients exposed to OTA. 
Moreover, OTA has also been detected in the serum of patients with BEN (O'Brien and 
Dietrich, 2005). These factors have resulted in the implication of OTA as an underlying 
factor in BEN (Stoev, 1998; O'Brien and Dietrich, 2005). 
2.5.1 Anatomy of the Kidney 
The kidneys are bean-shaped organs situated near the middle of the back, just below the rib 
cage. There are about 30000 to 34 000 nephrons (functional unit of the kidney) in each adult 
rat kidney (Madsen and Tisher, 2004). Each nephron consists of three portions: the vascular, 
glomerular and tubular element (Fig. 2.2). 
Structural organisation of the kidney includes the outer cortex, medulla and papilla. While 
the proximal and distal tubules, glomeruli and peritubular capillaries make up the cortex, the 
Loop of Henle and vasa recta make up the medulla. The papilla consists of the tenninal 
portions of the collecting duct and vasa recta (Madsen and Tisher, 2004). The kidney receives 
about 25% of the cardiac output, making it highly susceptible to toxicity. About 90% of the 
total renal blood flow is received by cortex, while the medulla and papilla receives 6% and 
1 %, respectively (De Broe and Roch-Ramel, 1998). 
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The glomerulus is a complex capillary network that filters blood into an ultrafiltrate. The 
glomerulus is also the first to receive exposure to a toxicant (Fig. 2.2). There are three 
barriers that the glomerular filtrate encounters, viz., the capillary endothelium, the capillary 
basement membrane and the visceral epithelium (podocytes) (Hladky and Rink, 1986; 
Schnellmann, 2003). Certain permeability-selective and charge-selective properties are 
present in the glomerulus. The permeability-selective property is directly related to the 
physicochemical properties of the different cell types within the glomerulus. 
Small molecules may freely pass through the glomerulus, while large molecules, however, 
cannot. Charge-selective properties are related to the anionic coating of the epithelial and 
endothelial cells and thereby restrict the filtration of anionic molecules (Schnellmann, 2003 ; 
Smart and Hodgson, 2008). Toxicants that neutralise or reduce the number of fixed anionic 
charges will therefore impair the charge or size-selective properties of the glomerulus 
(Smart and Hodgson, 2008). This results in the excretion of polyanionic and/or high 
molecular weight proteins. 
Next, the ultrafiltrate passes into the tubular portion of the nephron (Fig. 2.2), which begins at 
the proximal tubule and consists of the proximal convoluted and proximal straight segments. 
The proximal convoluted tubule plays a major role in the reabsorption of sodium (Na+), 
bicarbonate (HC03), potassium (K+) , calcium (Ca
2+), water and organic solutes such as 
glucose and amino acids. Filtered HC03-, proteins and glucose are reabsorbed in the proximal 
straight tubule. 
From the proximal tubule the filtrate passes into the Loop of Henle (Fig. 2.2). This portion is 
critical in concentrating urine. It is permeable to water at the thin descending limb, but after 
the loop the cells are impermeable to water. This allows for maximum reabsorption of water 
into the peritubular capillaries. From the Loop of Henle, tubular fluid moves to the distal 
tubule and then into the collecting duct. 
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Figure 2.2: Schematic of the kidney showing major blood vessels and the microcirculation of 
tubular components of each nephron (Schnellman, 2003). 
There are significant differences in energy metabolism among the various cell populations 
that line the nephron. Cells of the proximal convoluted tubule, thick ascending limb, distal 
convoluted and the collecting tubule are rich in mitochondria (Madsen and Tisher, 2004). 
These portions thus have a high capacity for oxidative energy production. 
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2.5.2 Disturbances Produced by Ochratoxin A in the Kidney 
The high blood flow rate and the presence of cellular transport systems makes the kidney 
susceptible to OT A. The effects of OTA may be dose-, time- and, often, species- and 
age-dependent (Gekle et ai. , 1995; Mally and Dekant, 2005). Using male Wistar rats as the 
experimental model, Schwerdt et al. (1996) showed that OT A-induced toxicity may change 
with age. In addition, OT A may be sex-specific, with male rats possibly being more 
susceptible than female rats (Castegnaro et al., 1998). 
Lesions confined to the proximal tubules were observed after OTA treatment (Domijan et ai. , 
2004). Hyaline deposits in the Bowman' s capsule and atrophy of the glomerulus were also 
noted (Ming-Fang Hseih et ai. , 2004). The increased renal cell proliferation was indicative of 
OT A carcinogenicity (Mally et al. , 2007). Furthermore, it is possible that renal toxicity may 
be a result of the accumulation of OT A in kidney tissue. 
In animal models, such as pig and rat, proximal and distal parts are affected by OT A 
(Stoev, 1998; Dahlmann et ai., 1998). Jung and Endou (1989) have shown that OTA alters 
only the middle and the terminal portions of the nephron. These authors demonstrated that 
OT A inhibited A TP synthesis in mitochondria but not in other segments. It was therefore 
proposed that OT A blocked mitochondrial respiration, and this may have induced the 
modification of intracellular calcium and subsequently reduced A TP (Simon et al., 1996; 
Schwerdt et ai., 2004). High adherence of OT A to organellar compartments corresponds with 
the uptake by mitochondria and may result in disturbances in cellular energy metabolism. 
Furthermore, OT A was responsible for disrupting mitochondrial respiration and oxidative 
phosphorylation through the impairment of the mitochondrial membrane and the inhibition of 
electron transfer (Wei et ai., 1985). This may subsequently reduce ATP production, which is 
required by the kidneys for the active reabsorption of water and other substrates. 
The disturbance in the calcium electrochemical gradient could also be a determining factor in 
deciding the fate of a cell, in terms of cell signalling and cell proliferation. This is of 
importance to the proximal tubule cells, which are rich in mitochondria and have various 
energy-requiring transport functions. Enzymes in the proximal tubule may also be disrupted 
11 
by OT A and may lead to polyuria, with reduced osmolality and morphological changes 
(Gekle and Silbemagl, 1994; Simon et al., 1996; Ming-Fang Hsieh et aI. , 2004). Moreover, 
OTA may decrease the glomerular filtration rate (Gekle and Silbemagl, 1996). 
2.6 APOPTOSIS 
Apoptosis refers to the controlled energy-dependent death of a cell and is also known as 
programmed cell death (PCD). The process of apoptosis takes place in a sequential series of 
steps that result in cells having specific morphological characteristics, such as cell shrinkage, 
condensation of chromatin and cytoplasm and DNA fragmentation (Hotchkiss and Nicholson, 
2006) (Fig. 2.3). In addition, mutations in the proteins that participate in apoptosis can lead to 
cancer development. 
Chromatin Condensation; 
Shrinkage of cytoplasm 
Nucleus fragmented; DNA 
"laddering"; Blebbing, cell 
fragmentation 
Figure 2.3: Diagrammatic representation of the morphological changes that take place during 
apoptosis (Becker et al., 2003). 
There are several phases that occur during cell death. These include induction, decision and 
execution/degradation. Induction/initiation is dependent on the nature of the death-inducing 
signal, i.e., the intrinsic or extrinsic signals (Kroemer et al., 2007) (Fig. 2.4). A pivotal role is 
played by a group of proteases (caspases) in the regulation of apoptotic cell death. 
Caspases (cysteine-dependent aspartate-specific proteases) are proteases that catalyse a 
cysteine (Cys)-mediated hydrolysis of peptide bonds which immediately follow aspartate 
(Rastogi et aI., 2009). Initially, proteases are produced in an inactive form called 
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pro-caspases (zymogens), which are then cleaved at two aspartate (Asp) sites to create the 
active enzymes (caspase) in a proteolytic cascade that usually involves other caspases 
(Desagher and Martinou, 2000; Rastogi et ai., 2009) (Fig. 2.4). The active caspases are a 
hetrotetramer of two large and two small sub-units. Caspases are divided into extrinsic 
(caspase-2, -8 and -10) and intrinsic (caspase-9) initiator caspases and executioner/effector 
(caspase-3, -6 and -7) caspases. The initiator caspases contain death domains, such as death 
effector domains (DED) (pro-caspase-8 and -10) or caspase recruitment domains (CARD) 
(pro-caspase-9 and -2) (Hengartner, 2000). These death domains facilitate the recruitment of 
caspases to work together with molecules that direct their activation, in response to intrinsic 
or extrinsic signals (Rastogi et ai., 2009). 
2.6.1 The Extrinsic Pathway 
The extrinsic pathway is a result of the activation of death receptors (ligand-induced) at cell 
surface. Death receptors, characterised by cysteine-rich extracellular domains and an 
intracellular cytoplasmic death domain (DD) sequence, include tumour necrosis factor 
receptor 1 (TNFR1), CD95IFAS and tumour-related apoptosis inducing ligand (TRAIL) 
(Kroemer et ai., 2007) (Fig. 2.4). When the ligand binds to the specific receptors, it leads to 
the attachment of adaptor proteins (FADD or TRADD) (Rastogi et ai., 2009) (Fig. 2.4). 
Procaspase-8 then associates with the adaptor proteins, resulting in a death inducing signalling 
complex (DISC) (Smart and Hodgson, 2008). Thereafter, caspase-8 is activated, which in 
tum triggers apoptosis. However, caspase-8 activation may be prevented by cellular 
caspase-8 (FLICE)-like inhibitory protein (cFLIP) (Hotchkiss and Nicholson, 2006; Smart 
and Hodgson, 2008) (Fig. 2.4). 
2.6.2 The Intrinsic Pathway 
Intracellular stress damage to DNA and ER induces the intrinsic pathway (Fig. 2.4). This 
pathway facilitates apoptosis due to an intracellular cascade of events and mitochondrial 
permeabilisation plays a critical role (Heiskanen et ai., 1999; Zamzami et ai., 1995; Desagher 
and Martinou, 2000; Mayer and Oberbauer, 2003; Kroemer et ai., 2007). Mitochondrial 
permeabilisation results from the opening of the permeability transition pore complex 
(PTPC), which is a transmembrane channel between the outer (OM) and inner mitochondrial 
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membranes (1M). The PTPC is formed through the interaction of the voltage-dependent-
anion channels (VDAC) in the OM and the adenine nucleotide transporter (ANT) in the 1M 
(Desagher and Martinou, 2000). This causes apoptotic effectors - such as cytochrome c, 
second mitochondria-derived activator of caspase/direct lAP protein with low pI 
(SmaclDiablo) and apoptosis inducing factor (AIF) - to leak out of the mitochondrial matrix 
(Kroemer et ai., 1997) (Fig. 2.4). 
Mitochondrial inner transmembrane potential (~'l'm) results from the asymmetric distribution 
of protons and other ions on both sides of the 1M. This results in a chemical and electrical 
gradient that is essential for oxidative phosphorylation and mitochondrial function 
(Kroemer et ai., 1997). The release of cyochrome c is thus usually followed by a collapse of 
the ~'l'm, known as permeability transition (PT) or mitochondrial depolarisation, and is used 
as one of the determining factors of apoptosis (Heiskanen et ai., 1999; Dubmann et ai., 2003; 
Kroemer et ai., 2007). 
Released cytochrome c binds to a cytoplasmic protein called the apoptotic protease activating 
factor-1 (Apaf-1) (Hotchkiss and Nicholson, 2006) (Fig. 2.4). Thereafter, procaspase-9 binds 
to cytochrome c and Apaf-1 to form a complex called the apoptosome (Fig. 2.4). This 
activates the initiator caspase-9, which cleaves other executioner caspases (-3 and -7), 
ultimately leading to apoptosis. Also, the activation of caspase-3 (via extrinsic and intrinsic 
pathways) results in phosphatidylserine externalisation on apoptotic cells, allowing for the 
early recognition and phagocytosis of apoptotic cells (Smart and Hodgson, 2008). 
Caspases are kept under tight control by specific proteins. These proteins belong to the Bcl-2 
family, which favour (Bax, Bid, Bik, Bak or Bad) or inhibit (Bcl2 or Bcl-XL) apoptosis 
(Petit et ai., 1996; Kroemer et ai., 1997) (Fig. 2.4). Bax and Bad facilitate apoptosis by 
binding to VDAC, thus stimulating permeabilisation of the outer mitochondrial membrane 
(Mayer and Oberbauer, 2003) (Fig. 2.4). This results in the leakage of cytochrome c out of 
the mitochondria into the cytoplasm. 
Crosstalk between the intrinsic and extrinsic pathways also leads to the activation of 
pro-apoptotic proteins. Caspase-8 can also proteolytically activate Bid, forming truncated Bid 
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(tBid), and induces membrane permeabilisation (Fig. 2.4). This represents the main link 
between intrinsic and extrinsic apoptotic pathways (Kroemer et ai., 2007). Furthermore, 
DNA damage may activate caspase-2, which may in turn promote the release of cytochrome c 
and other pro-apoptotic factors from the mitochondria (Guo et ai., 2002). 
Bel-2 and Bel-XL are mitochondrial proteins and inhibit apoptosis by blocking the release of 
cytochrome c from the mitochondria (Mayer and Oberbauer, 2003). However, the 
over-expression of Bel-2 may result in tumour formation. In addition to the Bel-2 
anti-apoptotic protein inhibitor of apoptosis proteins (lAPs) XIAP, c-IAPI and c-AIP2 are 
expressed in cells, which bind directly to and inhibit caspase-3 and -7 (Kroemer et ai., 2007; 
Rastogi et ai., 2009) (Fig. 2.4). 
There are various checkpoints present in the mitochondria that control apoptosis. Some of 
these signals are: cytosolic and organellar concentrations of protons, Ca2+, K+ and Na+, 
metabolites such as ADP/ATP, glutathione, kinases and phosphatases (Kroemer et ai., 2007). 
Exogenous factors, such as certain viral proteins and xenobiotics, playa role in determining 
apoptosis. Ultimately, a point is reached in which death-inducing signals may predominate 
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Figure 2.4: An illustration of apoptosis activation by the extrinsic pathway (left) and intrinsic 
(mitochondrial) pathway (right) and the role of caspases; ~ and t- represent activation and 
inhibition, respectively (Hotchkiss and Nicholson, 2006). 
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2.6.3 Apoptosis: A Factor in Ochratoxin A Toxicity 
Ochratoxin A-induced apoptosis was reported in vivo and in vitro (Petrik et al., 2003;Atroshi 
et al. , 2000; Gekle et al., 2000; Domijan et aI. , 2004; Kamp et al. , 2005). Features associated 
with apoptosis, such as DNA fragmentation, caspase-3 activity and chromatin condensation, 
were observed after OT A treatment (Seegers et al. , 1994a; Seegers et al., 1994b; Schwerdt et 
aI. , 2004). Additionally, apoptosis was demonstrated in kidney tissue after OTA treatment 
(Domijan et al., 2004; Petrik et aI., 2003). A study on male Wi star rats showed that OT A 
increased the number of cells undergoing apoptosis in tubular epithelial cells (Petrik et al., 
2003). 
It was noted in a study by Schwerdt et al. (2004) that the mitochondrial membrane potential 
was decreased in MDCK-C7 cells incubated with OT A, suggesting a role in OTA-induced 
apoptosis. A loss of mitochondrial potential could result in cellular energetic failure, Ca2+ 
overloading, generation of ROS, loss of osmotic regulation, and cell death. Ochratoxin A also 
caused disruptions in the pro- and anti-apoptotic proteins of the Bel family (Assaf et aI., 
2004). Furthermore, OTA produced oxidative stress (Omar et al. , 1990; Petrik et ai., 2003; 
Boesch-Saadatmandi et al., 2008), a trigger of apoptosis. 
Moreover, the pH of the cell influences OT A's effect on apoptotic induction. It is believed 
that a slightly basic pH may reduce the activation of caspase-3 and DNA ladder formation; 
however, the opposite is observed with an acidic pH (Blank and Wolffram, 2004; Schwerdt et 
aI. , 2004). In addition, OTA also increased apoptosis in immune cells (Seegers et ai., 1994b; 
Assaf et al., 2004). 
2.7 IMMUNOTOXICITY 
The immune system comprises several tissues and white blood cells which playa crucial role 
in defending the body against infectious agents (Smart and Hodgson, 2008). Immunotoxicity 
usually occurs when xenobiotic compounds produce unfavourable effects in the immune 
system. The immunotoxic effects of OTA have been studied in different experimental 
animals, particularly in rodents (Muller et ai. , 1999; Assaf et aI., 2004; Alvarez et ai., 2004; 
AI-Anati and Petzinger, 2006; Odhav et ai. , 2008). In mice, OT A produced a decreased 
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immune response after i.p injection (Prior and Sisodia, 1982). In this particular study the 
antibody response was decreased over a period of time, and this reduced the ability of the 
animal to respond to an immunological challenge. 
Ochratoxin A may also be associated with the inhibition of DNA synthesis in resting and 
activated T-Iymphoctyes. It has been postulated that OTA induces aberrations on X 
chromosomes of a similar type to those previously detected in lymphocytes from BEN 
patients (Stoev, 1998). 
The depletion of lymphoid cells and the suppression of antibody response was observed in 
rats after the oral administration of OT A. A decrease in T-cell response, natural killer (NK) 
cell activity and bacteriolytic capability of macrophages were also noted (Luster et ai., 1987; 
Stoev, 1998; Alvarez et ai., 2004). Furthermore, low concentrations of OTA decreased both 
NK and cytotoxic T-cell activities in vitro (Alvarez-Erviti et ai., 2005). Studies on pigs also 
revealed the immunotoxic potential of OTA (Muller et ai., 1999) where the production of 
ROS increased in whole blood and reduced lymphocyte levels. 
Odhav et ai. (2008) showed that OT A caused morphological changes in human lymphocytes 
and neutrophils. The featured morphological changes included cell membrane disruption, 
damage to cytoplasmic organelles and loss of nuclear integrity. These changes affected the 
immune response by increasing the susceptibility to various infections. A study by Assaf et 
ai. (2004) showed a decrease in mitochondrial membrane potential in OTA-treated human 
peripheral blood mononuclear cells (PBMCs). Ochratoxin A-induced immunotoxicity could 
occur as a result of protein synthesis inhibition and cell death, and may in tum cause a 
decrease in the number of immune-competent cells (Assaf et ai., 2004; Al-Anati and 
Petzinger, 2006). 
2.8 CELL SIGNALLING PATHWAYS 
The signalling pathways, such as those regulated by transcription factors or by kinases, may 
contribute to OT A toxicity. Mitogen-activated protein kinases respond to extracellular signals 
and transduce signals from the cellular membrane to the nucleus (Schilter et ai., 2005). 
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The MAPK pathway consists of a serial sequence of protein kinases that phosphorylate and 
regulate the respective downstream kinases, leading to the activation of MAPK. The 
mitogen-activated protein kinases have been suggested to play an antagonistic role upon OTA 
exposure (Marin-Kuan et aI., 2007). Extracellular signal regulated kinasesl and 2 (ERK1I2) 
are pro-mitotic, however, p38 and lun N-terminal kinase (JNK) support apoptosis, fibrosis 
and inflammation (Gekle et al., 2000; Sauvant et al. , 2005). A balance between these two 
groups may be important determinants of cellular fate, which was also shown using proximal 
tubular cells (Arany et aI., 2004; Barisic et al. , 2005). A study by Barisic et al. (2005) found 
a disruption in the balance of pro- and anti-apoptotic signals when cells were exposed to 
OTA. Furthermore, the activation of ERK112 was not strong enough to stimulate cell 
survival. 
2.9 EFFECT OF OCBRA TOXIN A ON PROTEINS 
Serum albumin is the most abundant protein in plasma. The binding of OT A to albumin 
results in a mobile reservoir that can slowly be released, thus retarding elimination (Kumagi, 
1985; Schwerdt et al., 1999; O'Brien and Dietrich, 2005). A study on albumin-deficient rats 
showed that OTA was eliminated faster in albumin-deficient rats than normal rats 
(Kumagi, 1985). The OT A mobile reservoir may contribute to the development of chronic 
diseases. It is believed that OTA binds to human serum albumin (HSA) as a dianion (OTA2-) 
at two sites and that the exact amino acid sequences at the binding sites are crucial in 
determining OT A binding (n 'ichev et al. , 2002; Grajewski et aI., 2008). 
Schwerdt et al. (1999) demonstrated that, proteins with molecular masses between 55kDa and 
60kDa, 40kDa and 45kDa, and 20kDa and 25kDa exhibited high OT A-binding capacity. 
These proteins included those from kidney proximal tubule cells of opossum (OK), pig 
(LLC-PKl), rat (SKPT) and human (IHKE). It was also shown that OTA bound to many 
proteins of rat organs, particularly proteins with molecular masses of 62kDa, 40kDa and 
26kDa. 
Ochratoxin A's primary mechanism of toxicity seems to be associated with the enzymes 
involved in phenylalanine (Ph e) metabolism viz., phenyl transferase and phenylalanine 
hydroxylase (P AH) (Zanic-Grubisic et al. , 2000). Furthermore, OT A compromises protein 
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synthesis by interacting with phenylalanine-handling proteins at the post-transcriptional level, 
such as phenylalanyl-tRNA-synthetase (Schwerdt et ai., 1999; Stoev, 1998; Simon et ai., 
1996; Marin-Kuan et ai., 2006). This alteration may have an effect on the production of 
tyrosine from phenylalanine. 
The organic anion transport (OAT) system in the proximal tubule is vital for the efficient 
removal of toxic compounds from the kidney, on a blood-to-Iumen basis (Russel et ai., 2002). 
This transport system consists of a basolaterally-Iocated organic anion exchanger, which is 
dependent upon the inward-directed Na+ gradient in order to drive the uptake of 
a-ketoglutarate (Groves et ai., 1998). a-Ketoglutarate is exchanged for p-amminohippurate 
(PAH) or any other competitive organic anion, subsequently resulting in the excretion of 
xenobiotics (Smart and Hodgson, 2008). It has been suggested that OT A may result in the 
impairment of organic anion secretion (Sauvant et ai., 1998). Gekle and Silbemagl (1994) 
found a reduced amount of renal secretion and clearance of pAH after a 6-day in vivo 
exposure to rats. An impairment of the OAT system may also be one of the reasons behind 
OTA's long half-life. Indirect toxic effects could also result from the organic anion transport 
disruption. 
The acute and chronic toxicity by OT A is related directly or indirectly to the inhibition of 
transport carrier proteins located in the inner mitochondria (Horvath et ai., 2002), which may 
lead to the inhibition of mitochondrial respiration. Furthermore, OTA-induced oxidative 
stress may disrupt protein function and impair its ability to carry out essential functions in the 
cell (Domijan et ai., 2005). 
In a study by Marin-Kuan et ai. (2006), elongation factor 1-alpha-1 (eFIA-l) was down 
regulated in OT A-treated samples. Elongation factor 1-alpha-1 promotes GTP-binding of 
aminoacyl-tRNA to the A-site of the ribosomes during biosynthesis. Therefore, if eFIA-l is 
inhibited, protein biosynthesis cannot take place. The same authors have also found that 
prostaglandin F2 receptor negative regulator and eukaryotic translation initiation factor 
4E binding protein 1 are up regulated upon OT A exposure. Both these proteins are involved 
in the negative regulation of protein synthesis. 
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2.10 POSSIBLE GENOTOXIC EFFECTS OF OCHRATOXIN A 
Genotoxicity refers to the alteration of genetic material, which can be caused by chemical 
compounds. These compounds can be described as genotoxins and can cause genetic 
mutations and tumours. If there is minor damage, the cell uses repair processes to return to an 
'undamaged'state. An enzyme known as Poly (ADP-ribose) polymerase (PARP) is involved 
in DNA repair, however, this function is inhibited when it is cleaved by caspase-3, one of the 
executors of apoptosis (Smart and Hodgson, 2008). 
The disruptions in normal cell cycle induced by OTA may constitute the underlying 
mechanisms of its carcinogenic and nephropathy-inducing activities (O'Brien et al. , 2001; 
Kamp et a/., 2005). Kamp et a/. (2005) observed a decrease in S-phase (synthesis) cells, 
while the GO (Resting)/G1 (Gap 1) cells increased. The decrease in the S-phase population 
was suggested to occur as a result of the inhibition of DNA replication. It is believed that 
DNA damage induced by OT A can begin at concentration levels which are not yet cytotoxic. 
Ochratoxin A treatment resulted in DNA strand breaks in the kidneys, livers and spleens of 
mice or rats when given either a single dose or by chronic administration in vivo (Creppy et 
a/., 1985; Kane et al., 1986; Zeljezic et a/. , 2006). In addition, OTA induced X-trisomy in 
cultured human lymphocytes (Manolova et a/. , 1990). Recently, genotoxic effects such as 
DNA strand breaks, sister chromatid exchanges, chromosomal aberrations and induction of 
micronuclei were detected in mammalian systems in response to OT A (Mally and Dekant, 
2005; Kamp et al., 2005). 
Ochratoxin A-induced DNA damage may occur by DNA-reactive genotoxic mechanisms or 
DNA non-reactive (epigenetic) genotoxic mechanisms. The direct interaction of a compound 
with DNA is referred to as the DNA reactive mechanism. During the biotransformation of 
OT A reactive intermediates may be formed which may bind to DNA and increase tumour 
formation. Gillman et al. (1998) hypothesised that DNA damage may occur due to the 
photo activation of OT A. The photoactivation of OT A may lead to the production of a 
reactive quinone derivative responsible for OTA's DNA adduction properties. Studies 
conducted in vivo (mice and rats) showed DNA adducts after OTA treatment 
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(Obrecht-Pflumio et ai., 1996; Castegnaro et al., 1998). However, it is believed that DNA 
adducts could be formed by secondary effects in vivo (Obrecht-Pflumio and Dirheimer, 2000). 
The DNA non-reactive mechanism is therefore becoming prominent (Gautier et al., 2001a; 
Marin-Kuan et ai., 2008). This implies that DNA damage may occur through the generation 
of ROS or cytotoxicity (Zepnik et al., 2001; Kamp et ai., 2005; Arbillaga et ai., 2007a). It 
was also evident from previous studies (Schlatter et al., 1996; Gautier et ai., 2001a) that 
although DNA damage occurred, DNA adduct formation was not observed or it was below 
the level of detection. 
2.11 THE MEDICINAL PLANT SUTHERLANDIA FRUTESCENS 
Sutherlandia Jrutescens (Fig. 2.5), a flowering bush-type plant, belongs to the Pea family 
(Fabaceae) and is native to South Africa's Western Cape and Karoo region. Sutherlandia 
Jrutescens has been used in the treatment of cancer, tuberculosis, diabetes, chronic fatigue 
syndrome, influenza, rheumatoid arthritis, osteoarthritis, reflux oesophagi tis, anxiety and 
clinical depression (Chinkwo, 2005; Mills et ai., 2005; Chadwick et al., 2007). Currently, 
S. Jrutescens is being used in South Africa in the treatment of HIV/AIDS; it helps improve 
mood and appetite, and is also helpful in increasing CD4 counts and reducing viral loads. 
Based on primate safety studies, the South African Ministry of Health has concluded that 
S. Jrutescens is safe to use (Mills et al., 2005; Seier et al., 2002). 
Figure 2.5: An illustration of the Sutherlandia Jrutescens plant: A) The medicinal plant 
showing flowers and leaves; B) Flowers and pods; C) Dried product (leaves) that will be used 
commercially (van Wyk and Albrecht, 2008). 
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The leaves of this plant contain L-canavanine (L-CA V), D-pinitol and y-aminobutyric acid 
(GAB A) (Fig. 2.6). Free amino acids, asparagine, proline and arginine have also been 
identified in S. Jrutescens (van Wyk and Albrecht, 2008). This medicinal plant also contains 
phenolic compounds, such as flavonoids and tannins. 
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Figure 2.6: Chemical structures of the major compounds found in Sutherlandia Jrutescens 
(Davis et al., 2000; van Wyk and Albrecht, 2008). 
The leaves of S. Jrutescens may serve as a hypoglycaemic agent for the treatment of 
type-2 diabetes (Chadwick et al., 2007). This may be attributed to the presence ofD-pinitol, a 
type of sugar, which shows potential as a therapeutic agent in the treatment of diabetes 
(Sia, 2004; van Wyk and Albrecht, 2008). D-Pinitol stands out as it may improve glucose 
metabolism and thereby increase cellular energy and help reduce fatigue (van Wyk and 
Albrecht, 2008). In addition, GABA, a weak acid and inhibitory neurotransmitter, may also 
serve as a possible anti-tumour agent, which may prevent metastasis in vivo (Tai et al., 2004). 
L-canavanine is an L-arginine (L-ARG) analogue (Fig. 2.7), present in large quantities in the 
leaves of S. Jrutescens. It is a non-protein amino ' acid, also known as a secondary or 
anti-metabolite. As a result, it is not usually used to synthesise cellular proteins but is known 
to replace L-ARG and produce aberrant canavanyl or non-functional proteins (Akaogi et al., 
2006). Subsequently, L-CAV, may affect the tertiary and/or quarternary structure unique to 
the protein (Bence and Crooks, 2003). 
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It is suggested that L-CA V competes with L-ARG cellular enzymes such as arginyl tRNA 
synthetase, inducible nitric oxide synthetase (iN OS) and arginase (Akaogi et al., 2006). 
L-canavanine is useful in treating many ailments and assists in the breakdown of about 20 
amino acids. Each leaf may contain 2.2 - 3mg of L-CAV, which has anti-bacterial, 
anti-fungal and anti-viral activities (Sia, 2004). Furthermore, L-CA V and its major metabolite 
canaline may also have anti-tumour properties and are being used as anti-cancer drugs since 
they tend to induce apoptosis (Tai et al., 2004; Chinkwo, 2005). Protein synthesis, as well as 
RNA and DNA metabolic pathways, may also be altered by L-CAV (Worthen et al., 1998). 
A B 
Figure 2.7: Chemical structures of L-canavanine (A) and L-arginine (B) (Bence and Crooks, 
2003). 
It was also suggested that S. frutescens could possibly act as an irnrnunomodulator for the 
treatment of diseases associated with an overproduction of reactive oxidants (Fernandes et al., 
2004). Furthermore, S. frutescens was identified as being anti-mutagenic (Reid et aI., 2006). 
Therefore this plant could also have the potential to act as an anti-carcinogenic and 
chemo-preventative agent. 
Since the complete avoidance of OT A in food is difficult, it is imperative to understand the 
effects of OT A on the body. Studies concerning OT A are important seeing that this toxin is 
found in a wide variety of food items ingested by both humans and animals. According to the 
existing literature, OT A produces a number of undesirable cell alterations in the kidneys. 
Since the kidneys have the important function of eliminating waste from the body, 
understanding the mechanisms by which OT A induces toxicity is vital. Thus by investigating 
the mechanisms involved in OT A toxicity the socioeconomic implications that OT A produces 
may be minimised. 
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CHAPTER 3 
ANIMAL TREATMENT AND SAMPLE STORAGE 
3.1 ANIMAL ETHICS 
Animal ethics was approved by the University of KwaZulu-Natal Ethics Committee (Faculty 
of Health Sciences) (Reference number 022/07/Animal). All animal procedures, i.e., 
injecting, bleeding and animal handling were performed by trained experts in the field of 
animal handling. These individuals included a registered veterinarian, veterinarian 
technologist and technicians at the Biomedical Resource Unit (University of KwaZulu-Natal), 
where the animals were housed. 
3.2 ANIMAL TREATMENT 
Male Wistar rats (Rattus novergicus), weighing between 200 - 300g, were used. The rats 
were randomly chosen, weighed and then acclimatised for three days prior to treatment. 
Animals were housed in metabolic cages and were allowed free access to normal food and 
water. Rats were treated with either vehicle only (EtOH:H20; 30:70), S. frutescens extract 
(Phyto Nova Natural Medicines (S.A», Ochratoxin A (OTA) (Sigma-Aldrich (S.A) or a 
combination of OT A and S. Jrutescens extract. Ochratoxin A was administered at 0.5mg/kg 
body weight (Schwerdt et ai., 1996; Zeljezic et ai., 2006) and S. Jrutescens extract at 
1.0mg/kg body weight (Stander et ai., 2007) by intraperitoneal (i.p) injection. Both OT A and 
S. Jrutescens extract were diluted with the vehicle prior to injection (Appendix A). Rats 
received treatments (vehicle only, S. Jrutescens extract, OTA-only or a combination of OTA 
and S. Jrutescens extract) for a period of only 1 day (Day 1) or 7 consecutive days (Day 7). 
Therefore, animals were divided into eight groups, with four rats in each group (Table 3.1). 
During the period that the rats were observed under treatment, a drop of tail blood 
(approximately 20JJl) was taken on Day 0, Day 1 and Day 7, for the Comet Assay. The rats 
were placed in a warm chamber for 1 - 2 minutes. A tube restrainer was used to restrain the 
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animals, leaving only the tail exposed. The lower part of the tail was swabbed with a 
disinfectant. Thereafter, a sterile 1 inch, 23 gauge injection needle was used to prick the tail. 
After the required time periods (1 day and 7 days), each rat was placed in an inhalation 
chamber that contained anaesthetic halothane. As soon as breathing stopped, animals were 
removed, exsanguanated, and organs harvested. 
Table 3.1: Animal treatment and duration 
Group Animal Treatment Duration 
Group 1 Control (n=4) 1 day 
Group 2 S frutescens only (n=4) 1 day 
Group 3 OTA only (n=4) 1 day 
Group 4 OTA and Sfrutescens (n=4) 1 day 
Group 5 Control (n=4) 7 days 
Group 6 S frutescens only (n=4) 7 days 
Group 7 OTA only (n=4) 7 days 
Group 8 OTA and S. frutescens (n=4) 7 days 
3.3 BLOOD COLLECTION 
On the day of organ harvest, rat blood was collected by cardiac puncture. This method was 
selected based on its ease and rapidity with minimal contamination. A combined volume of 
6ml blood was collected for each rat in two types of blood tubes. Heparinised tubes were 
used for whole blood collection and tubes containing serum gel were used for serum. 
3.4 BLOOD SEPARATION 
Following blood collection from each rat, bloods were immediately separated in order to 
obtain peripheral blood mononuclear cells (PBMCs). All handling of blood was carried out 
under a safety cabinet equipped with a vertical laminar flow. 
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For better separation, blood was mixed with an equal amount of phosphate buffered saline 
(PBS) (Merck (S.A). Thereafter, the blood-PBS mixture was layered onto an equal volume of 
Histopaque-1077 (Sigma-Aldrich (S.A) (approximately 3ml) and the samples were 
centrifuged (25 min, 2 500rpm, room temperature (RT». Histopaque-l077, adjusted to a 
density of 1.077±0.00 1 glml, is a mixture of polysucrose and sodium diatriozoate and helps in 
the recovery of viable mononuclear cells from small volumes of blood. 
After centrifugation, three distinct layers were obtained: plasma, PBMCs (buffy coat) and red 






Red Blood Ce.lls 
Figure 3.1: Separation of peripheral blood mononuclear cells from whole blood usmg 
Histopaque-l 077. Three distinct layers are formed: plasma, mononuclear cells and red blood 
cells (Sigma-Aldrich, 2003). 
The top layer (plasma) was carefully removed and aliquoted into cryovials, and stored (-80°C) 
for future use. Care was taken not to touch the buffy coat layer, as removal of this layer 
reduces the number of PBMCs obtained. Next, PBMCs were aspirated and transferred into 
eppendorfs. Isolated PBMCs were then washed with PBS (15 min, 3 500rpm). The 
supernatant was discarded and the pellet obtained was re-suspended in PBS (7001l1). 
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3.5 CELL COUNTING 
Thereafter, PBMCs were counted usmg a haemocytometer. This device consists of a 
thickened glass slide that has a small chamber of grids that is cut into the glass. The chamber 
has a fixed volume and has 9 large squares etched into it. Each large comer square contains 
16 smaller squares. The large squares measure 1mm x 1mm and are O.1mm deep. The cell 
suspension (101l1) (SOIlI trypan blue stain, SOIlI complete culture media and SOIlI PBMCs) 
was loaded into a clean haemocytometer chamber. Cells within the 4 comer squares 
(orange squares in Fig. 3.2) were counted with the aid of an inverted microscope, set at 400x 
magnification. 
Trypan blue (Merck (S.A)) was mixed with PBMCs in order to differentiate the viable cells 
from the dead cells. The dye is taken up by dead cells, but is excluded from live cells. As a 
result, viable cells appear as bright transluscent structures while dead cells stain blue. When 
counting cells, only cells touching the top and left borders were counted, while those touching 
the bottom and right borders were excluded (Fig. 3.2). The count was mathematically 
converted to number of cells/cm3 and the cell number was adjusted to 1 x 106 cells/ml. Cell 
viability was calculated according to the following equations: 
Cells per ml= Average count per square x dilutionfactor x 104 
Total cells = (Cells per ml x (original volume of fluid from which cell sample was taken)) 
o = viable cells e = dead cells 
e = cells on bottom and 
right borders 
1/16 sq. mm 
(Count) 
(Do not count) 
(Do not count) 
Figure 3.2: Illustration of the cell counting procedure. 
1 mm 
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Peripheral blood mononuclear cells (PBMCs) were then used to assay for apoptosis and cell 
viability using flow cytometry and the methylthiazol tetrazolium (MTT) assay, respectively. 
3.6 CRYOPRESERV ATION 
Cryopreservation serves as an excellent way to sustain cells and provides a renewable source 
that could be used in the future. Therefore, an aliquot of PBMCs were cryopreserved for 
future use. The PBMCs were mixed with (1.5ml) cryosolution (90% foetal calf serum 
(Gibco) and 10% dimethyl sulphoxide (DMSO)). Freezing can result in the formation of 
ice-crystals and changes in the concentration of electrolytes and pH (Wilson and Walker, 
2005). Dimethyl sulphoxide (DMSO) (Merck (S.A)) was therefore used as a cryoprotectant 
as it lowers the freezing point and prevents ice-crystal formation inside the cell. The addition 
of foetal calf serum ensured that the cells also had a good supply of nutrients. The 
cryosolution was added to the PBMCs in a drop-wise manner. Cryosolution and PBMCs 
were thoroughly mixed, and was then placed in a nalgene cooler. The nalgene cooler allowed 
the temperature to decrease by -1°Clmin and required the addition of 100% isopropanol 
(Merck (S.A)) and mechanical freezing (-80°C). 
3.7 ORGAN STORAGE 
After the organs were harvested, the organs of interest, the kidneys, were initially bisected and 
then further cut into smaller pieces. A portion of this tissue was placed into labelled vials 
according to each treatment and immediately snap-frozen in liquid nitrogen at the Biomedical 
Resource Unit. This tissue was stored (-80°C) and then later used for protein analysis. 
The rat kidneys were also used for histological analysis. Therefore, a fraction of the kidney 
tissue collected on the day of harvest (as described above) was immediately immersed in 
Finefix solution (Apollo Scientific). This was done to preserve the tissue in a life-like 
manner, to prevent tissue autolysis and to protect it from the processing that follows 
thereafter. Tissue may dry if it is not fixed directly after harvest, which may lead to artefact 
formation, nuclear shrinkage and cellular organelles may be damaged. The tissue was placed 
in Finefix solution for approximately 12 hours before processing. 
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CHAPTER 4 
MET ABOLIC ACTIVITY OF PERIPHERAL BLOOD 
MONONUCLEAR CELLS FROM OCHRATOXIN A TREATED 
MALE WIST AR RATS 
4.1 INTRODUCTION 
When cells are treated with a cytotoxic compound they may undergo either apoptosis or 
necrosis. Cytotoxicity does not however identify the specific cell death mechanism. A cell 
cannot survive without a source of energy and chemical building blocks. This energy is 
obtained from metabolism. 
Metabolism refers to the chemical processes that take place in a cell. Harvesting of energy is 
one of the endpoints of metabolism. The mitochondrion is often referred to as the 'energy 
powerhouse'; this is because most ATP generation occurs in the mitochondria. The 
tricarboxylic acid (TCA) cycle (central oxidative pathway in respiration) and electron 
transport occur within the matrix of the mitochondria. Most of the energy released by 
oxidations in the TCA cycle is trapped in the electrons carried by NADH and F ADH2• These 
electrons then enter the electron transport chain in order to drive the synthesis of A TP. Due to 
cellular damage, the energy required for metabolic cell functions and growth can be reduced. 
Cellular metabolic activity can be measured by the use of tetrazolium salts. Tetrazolium salts 
are used extensively in cell proliferation and cytotoxicity assays, enzyme assays, 
histochemical procedures and bacteriologic screening (Berridge et ai., 1996). A distinct 
chromogenic product (formazan) is formed in each of the above-mentioned procedures 
(Berridge et ai., 1996). 
The methylthiazol tetrazolium (MTT) assay is a quantitative colorimetric method, based on 
the reductive cleavage of the water-soluble monotetrazolium salt MTT (3-[ 4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), a pale yellow substrate which yields 
a purple formazan product (Mosmann, 1983). Since formazan is insoluble, it is solubilised 
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using an appropriate solvent, and thereafter the absorbance of the solution can be determined 
using a spectrophotometer. Formazan is directly correlated with metabolically viable cells. 
Therefore, an increase in the number of viable cells results in an increased absorption of the 
solution (Bernhard et ai., 2003). The MTT assay thus measures the cell proliferation rate and 
viability, based on metabolic activity (Bernhard et ai., 2003). 
Only viable (metabolically active) cells can convert MTT to formazan, therefore, MTT is 
actively transported into viable cells where the tetrazolium ring is cleaved. One mechanism 
for the reduction of MTT to formazan occurs via the succinate-tetrazolium reductase system 
(mitochondrial respiratory chain) (Bernhard et ai., 2003). It was shown that MTT reduction is 
also dependent upon the amount of reduced nicotinamide dinucleotides NADH and NADPH 
(Berridge and Tan, 1993). The MTT assay is sensitive, quick, requires a reduced number of 
cells, and allows a large number of samples to be processed simultaneously. 
Cytotoxic agents may reduce the cells' ability to cleave MTT to formazan. Ochratoxin A is 
widely known to be cytotoxic to cells. Subsequently, cell viability and metabolic activity 
were determined in PBMCs of rats treated with OT A. Furthermore, the cyto-protective 
effects of S.frutescens on PBMCs from OTA treated rats were also examined. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
MTT salt was purchased from Calbiochem (S.A.); Dimethyl sulphoxide (DMSO) and PBS 
tablets were obtained from Merck (S.A.); 96 well microtiter plates were purchased from the 
Scientific Group (S.A.). All other chemicals were purchased from Merck (S.A.). 
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4.2.2 Methods 
4.2.2.1 Methylthiazol Tetrazolium Assay 
Peripheral blood mononuclear cells (PBMCs) were isolated by differential centrifugation, as 
discussed in Chapter 3. 
A SOfll PBMC aliquot (1 xl 06 cells/ml) from each treatment was added to a 96 well microtiter 
plate. Methylthiazol tetrazolium (Smg/ml) salt solution (in PBS, pH 7.4) (1OJll) was then 
added to each well containing PBMCs. These steps were performed in a safety cabinet 
equipped with a vertical laminar flow hood, to ensure that the cell suspension was protected 
from any foreign particles that may affect the experiment. 
Cells were then incubated (1 hr, 37°C), to allow for the reaction to take place. Thereafter, 
cells were centrifuged (10 min, 2 OOOrpm, RT). After centrifugation, the supernatant was 
discarded and DMSO (200fll) was added to each well. Dimethyl sulphoxide is a polar aprotic 
solvent (cannot donate hydrogen) and dissolves both polar and non-polar compounds. 
Therefore, DMSO solubilises the formazan (insoluble) product formed. Cells were 
re-incubated (30 min, 37°C). Thereafter, the optical density was measured 
spectrophotometrically at a wavelength of S90nm, with a reference wavelength of 6SSnm, 
using a Quant ELISA plate reader (Analytical Diagnostic products (S.A.)). 
The assay was performed in triplicate and mean cell viability was calculated by comparing the 
absorbance of each treatment to that of the control: 
Cell Viability (%) = (Mean absorbance of treatment cellS) x 100 
Mean absorbanceof control cells 
4.2.3 Statistical Analysis 
Statistical significance was determined using One-Way Analysis of Variance (ANOVA) and 
the Tukey-Kramer Multiple comparisons test on GraphPad Instat v3.06 (GraphPad Software, 




In order to detennine statistical significance, treatments were initially compared with the 
control for the same durations. Thereafter, comparisons were made between the Day 1 and 
Day 7 regimes. The PBMC viability of the rat control groups (Group 1 and Group 5) was 
100% (Fig. 4.1). 
Statistical analysis showed that there were significant increases in PBMC viability after the 
S. Jrutescens (Group 2), OT A-only (Group 3) and combination (OTA and S. Jrutescens) 
(Group 4) Day 1 treatments when compared to the control (p<0.001) (Fig. 4.1). While 
treatment with S. Jrutescens-only (Day 1) resulted in a 168.8% viability, the OTA-only and 
combination treatments both produced PBMC viabilities of 208% after 1 day (Fig. 4.1). No 
significant difference in viability was observed between the OT A-only and combination 
treated rat PBMCs (Day 1). However, rats treated with a combination of OTA and 
S. Jrutescens exhibited a significantly higher (l.23-fold) PBMC viability after Day 1 than did 
the rats treated only with S.frutescens (p<0.001) (Fig. 4.1). 
Following a 7-day treatment, the OTA-only treated rat group (Group 7) showed a significant 
decrease (7.14-fold) in PBMC viability (14%) compared to the control (Day 7) (p<0.001) 
(Fig. 4.1). The PBMC viability of the combination-treated rat group (73%) (Group 8) was 
1.37-fold lower compared to the control (p<0.05) (Fig. 4.1). No significant difference was 
observed between the PBMC viabilities of the S. Jrutescens (Group 6) (106%) and control rat 
groups. In addition, PBMCs from the combination-treated rats (7 days) showed a 
significantly higher (5.21-fold) PBMC viability than did those treated with OTA alone 
(p<0.001). The results also show a significantly lower (l.45-fold) PBMC viability in the 
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• Day 1 000 ~ Day 7 
*** *** 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 
Group I - Control Day I 
Group 2 - S. frutescens-only Day I 
Group 3 - OT A-only Day I 
Group 4 - OT A and S. frutescens Day I 
Treatment 
Group 5 - Control Day 7 
Group 6 - S.frutescens-only Day 7 
Group 7 - OT A-only Day 7 
Group 8 - OT A and S. frutescens Day 7 
Figure 4.1: Measurement of peripheral blood mononuclear cell viability by the MTT assay. 
Data represent the mean ±SEM (n=4). Comparisons were made with controls and between 
Day 1 and Day 7 treatments. * represents comparison with control *p<0.05 ***p<O.OOI. 
,. represents comparison between Day 1 and Day 7 treatments """p<O.OOl. + represents the 
comparison between OTA-only and the co-treatment +++p<O.OOl. ° represents comparison 
between s.Jrutescens-only and the combination group oop<O.01 ooop<O.OOl. 
In order to determine the effect of treatment duration on toxicity, comparisons in PBMC 
viability were made between the Day 1 and Day 7 treatments. The viability of PBMCs from 
the S. Jrutescens treated rats after 7 days was 106% (Fig. 4.1); this was significantly lower 
(1.59-fold) than the Day 1 treatment (168.8%) (p<0.001). After a period of7 days, the PBMC 
viability of the OTA-only treatment was 14% and this was 14.85-fold lower than the Day 1 
regIme (p<0.001) (Fig. 4.1). Furthermore, there was a significant decrease 
(2.85-fold) in PBMC viability when rats were treated with a combination of OTA and 




The reduction of tetrazolium salts in the MTT assay is dependent upon metabolic activity, 
which in turn determines cell viability. An increase in viability means that the cells are 
metabolically active. Peripheral blood mononuclear cell viability of the S. frutescens-only 
treatment group was higher than the control after 1 day. D-Pinitol is known to have 
anti-diabetic effects; it acts like insulin and promotes glucose transport and glycogen 
synthesis, and therefore increases energy production (van Wyk and Albrecht, 2008). 
Subsequently, an increase in PBMC viability after the Day 1 S. frutescens-only treatment may 
have been due to the D-Pinitol activity, and thus the MTT activity in these cells was high. 
However, the PBMC viability of the S. frutescens-only treated rats significantly decreased 
after 7 days when compared with the Day 1 S. frutescens treatment. Thus, it is possible that 
with repeated doses, S. frutescens may be more effective. A high PBMC viability was 
maintained after 7 days at 106%, which suggests cells were still metabolically active. 
An increase in rat PBMC viability after the Day IOTA-only and combination treatment 
indicates that metabolic activity in these cells was high. Furthermore, it is possible that OT A 
may affect cellular signalling and regulation, creating a mitogenic effect, which may result in 
an increase in glucose utilisation and therefore, the increased metabolic activity. In addition, 
the increase in cell viability after the Day 1 treatment could be a possible stress-response 
mechanism. It is also known that a degree of toxicity may induce cell regeneration and 
proliferation, which may increase the risk of various genetic errors and subsequently lead to 
cell transformation and tumour development (Schilter et aI., 2005). 
A decrease in PBMC viability of the OTA-only treated rats after 7 days suggests that the time 
period in which the toxin was in the body may have had converse effects. As previously 
mentioned, the presence of OT A in the body for an extended period of time could result in 
cell death (Schwerdt et ai., 2007). It is believed that mitogen-activated kinases (MAPKs) may 
play an antagonistic role upon OTA exposure (Marin-Kuan et aI., 2007; Marin-Kuan et at., 
2008). Insulin is the main hormone responsible for glucose uptake in cells and its functions 
are dependent on MAPK signalling. If OT A causes disruptions in MAPKs, it is possible that 
the insulin function may be hampered and that the glucose uptake into cells will be decreased. 
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NADH production in the cell will thus be reduced, resulting in a decrease in dehydrogenases, 
which subsequently decreases cell viability. It is possible that this may have occurred after 
the 7-day OTA-only treatment. This alteration of insulin function may lead to diabetes and, if 
not treated, ultimately lead to severe kidney disease. 
Immune cells such as lymphocytes can utilise glutamine, in addition to glucose, at high rates 
and glutamine is required for both lymphocyte proliferation and cytokine production (Mates 
et al., 2002; Newsholme et aI., 2003). The immediate product of glutamine metabolism is 
L-glutamate (Newsholme et al., 2003). The conversion of glutamine to glutamate ultimately 
results in a-ketoglutarate, an intermediate of the TeA cycle, through transamination. 
Initially, the amino group of glutamine is hydrolysed, thus yielding glutamate and ammonium. 
Glutamate is then further metabolised to a-ketoglutarate. Thus, if there is a decrease in the 
conversion of glutamate to a-ketoglutarate, subsequent steps in the TeA cycle will be 
minimised. This leads to a reduction in the production of NADH and therefore the reduction 
of formazan production. This would alter the TeA cycle and energy production would 
therefore be decreased leading to a lower cell viability, which was noticed in the OT A-only 
treated rats on Day 7. a-Ketoglutarate is important in the TeA cycle and is therefore linked 
to A TP production. 
Although a-ketoglutarate is produced by mitochondria in the kidney, blood concentrations are 
also important. A TP is vital to the kidney because of the active transport that takes place. 
Furthermore, a-ketoglutarate is known to be important in the movement of xenobiotics or 
drugs from the blood into the kidney, where it is excreted (Smart and Hodgson, 2008). 
However, when the level of a-ketoglutarate in kidney cells decreases, the a-ketoglutarate 
produced in the blood will be transported into the kidney cells. Any changes in 
a-ketoglutarate in the lymphocytes therefore affects the kidneys. As has been shown in other 
studies, OT A may be responsible for altering mitochondrial function (AI eo et aI., 1991; 
Bouaziz et al., 2008), and this in tum may be the result of disruptions in the glutamine 
metabolism. 
In order to maintain high rates of glutaminolysis (despite the plasma level of glutamine), the 
flux through the glutaminolytic pathway is controlled (Newsholme et al., 1985). Therefore, 
36 
.. 
factors such as: glutamine transport across the cell and mitochondrial membranes; 
glutaminase and oxoglutarate dehydrogenase; and changes in intracellular Ca2+, may playa 
pivotal role in controlling glutaminolysis (Newsholme et ai. , 1985). It is owing to the loss of 
control of these factors that glutaminolysis may have decreased, thus altering the conversion 
of glutamine to a-ketoglutarate. 
It is also believed that white blood cells and immune cells migrate to OT A-damaged organs 
(such as the kidney and liver), and this reduces the number of immune cells in the 
bloodstream (AI-Anati and Petzinger, 2006). The disruption of cell proliferation, interference 
with cell surface receptors, signalling pathways or metabolic activities may be responsible for 
alterations in the immune response. A decreased number of immune cells in the bloodstream 
results in sensitivity to infections due to the suppression of humoral and cell-mediated 
immune response. The results of the present study show that OT A is not only cytotoxic, but it 
is also highly immunotoxic, as has been shown in other studies (Alvarez et ai., 2004; Alvarez-
Erviti et ai., 2005). 
Sutheriandia frutescens is believed to have anti-proliferative effects (Tai et ai. , 2004; Reid et 
ai. , 2006 and van Wyk and Albrecht, 2008). An analysis ofthe Day 1 combination treatment, 
however, showed that PBMC viability was significantly higher than that of the control. It 
should also be noted that there was no significant difference between the co-treatment and 
OTA-only group after Day 1. It is possible that the anti-proliferative effects of S. frutescens 
may not have been effective after the Day 1 treatment. Instead, OT A and S. frutescens 
together continued to increase PBMC viability. 
The PBMC viability of the 7-day combination regime (Group 8) was significantly lower than 
that ofthe Day 1 treatment (p<0.001) (Fig. 4.1). It has been suggested that for S.frutescens to 
be effective in vivo, its active ingredients must be absorbed and presented to the targets at 
concentrations that can actually exert an effect (Tai et ai. , 2004). Therefore, the repeated 
injection of doses of S. frutescens into rats could ensure the effectiveness of this medicinal 
plant. While the OT A-only treatment (Day 7) resulted in an extremely low cell viability, 
treatment with the combination of OTA and S. frutescens significantly increased cell viability 
after 7 days compared to the control (Fig. 4.1). Considering that D-pinitol may have 
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insulin-like effects, it is possible that D-pinitol may have counteracted any disruption in 
insulin function which OT A may have caused. It is evident that only after a period of 7 days 
did the plant's properties become effective in assisting in the maintenance of cell viability. 
The results thus point to S. Jrutescens protective role towards immune cells. 
Anti-proliferative effects of S. Jrutescens have been studied using various cancer cell lines 
(Tai et aI., 2004; Stander et ai., 2007). Active compounds in S. Jrutescens are believed to 
produce these anti-proliferative effects. The diverse biological activities of L-CA V have led 
to the evaluation of its potential as an anti-cancer agent (Worthen et aI., 1998). L-canavanine 
has been shown to bring about anti-proliferative effects in vivo. Being an L-ARG analogue, 
L-CAV can replace L-ARG. L-canavanine is less basic and slightly longer than L-ARG, and 
it exists in an amino rather than an imino tautomeric fonn (Bence and Crooks, 2003). The 
incorporation of L-CA V can therefore affect the quarternary structure of proteins and can lead 
to changes in growth. 
It is believed that the anti-proliferative effects of L-CA V are the result of its conversion to the 
arginase metabolite, L-canaline, which can disrupt biochemical pathways involving 
L-ornithine and polyamines (Bence et ai. , 2002). Both L-ornithine and polyamines influence 
cell growth. L-ornithine may increase the levels of growth-promoting honnones, such as 
insulin and growth honnone, and if cellular polyamine synthesis is stopped, then cell growth 
is inhibited. It is now also believed that the major triterpenoids of S. Jrutescens are closely 
related in structure to cycloartane-type triterpenoids, which have proven cancer 
chemopreventive activities (van Wyk and Albrecht, 2008). Subsequently, these 
antiproliferative effects may have resulted in the decreased PBMC viability noticed after the 
7 day (Group 7) S. Jrutescens and combination regime, as compared with Day 1 (Group 3) 
regimes (Fig. 4.1). 
Furthennore, GABA is a weak acid and disrupts mitochondrial polarity. When mitochondria 
are fully polarised, they will produce more ATP. GABA, however, decreases mitochondrial 
membrane polarity and A TP production, thus reducing cell viability. This may therefore have 
resulted in a reduced source of energy and subsequently a reduced PBMC viability, shown at 
Day 7 in the OTA and S. Jrutescens combination treatment (Group 8) and also in the 
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S. frutescens-only group (Group 6) (Fig. 4.1). Together with this, OTA also causes 
disruptions in mitochondrial oxidative phosphorylation through the succinate-dependent 
electron transfer activities (Wei et ai., 1985). This may also be a reason behind the reduced 
PBMC viability noticed after the OT A-only and combination treatments. 
4.5 CONCLUSION 
Peripheral blood mononuclear cell viability, when rats were treated with OT A alone or with 
the combination of OTA and S. frutescens for 1 day, was significantly higher than the control. 
Drastic changes were observed after the 7 -day treatment with OT A alone, which caused the 
PBMC viability to decrease. These results confirm the immunotoxic potential of OT A. In 
addition, the results indicate the possible (immuno) protective role of S. frutescens. 
Ochratoxin A exerted its toxic effects on PBMCs in a time-dependent fashion. 
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CHAPTERS 
GENOTOXIC EFFECTS OF OCHRATOXIN A ON RAT PERIPHERAL 
BLOOD MONONUCLEAR CELLS 
5.1 INTRODUCTION 
Genotoxicity is the field of toxicology that assesses the effect of chemicals or xenobiotics on 
DNA and/or RNA of living organisms (Smart and Hodgson, 2008). The nucleus is the site 
where genotoxic agents exert their toxicities. Eukaryotic chromosomes contain DNA 
(50-100cm in length) and have to be condensed 105 fold to fit within a nucleus of 5-lOJlm 
(Mckelvey-Martin et ai., 1993). However, the occurrence of DNA damage is possible. DNA 
damage can include single and double strand breaks in the DNA backbone, cross-links 
between DNA and DNA bases and proteins, as well as chemical additions to DNA base pairs 
(adducts) (Smart and Hodgson, 2008). Chemicals can also intercalate between base pairs. In 
normal living cells high molecular weight chromosomal DNA is contained within the nucleus, 
but there is no DNA in the cytoplasm. In apoptotic cells, deoxyribonuclease (DNase) 
activation leads to low molecular weight fragments in the cytoplasm and the nucleus. The 
amount of high molecular weight uncleaved DNA declines in the nucleus because of the 
action of endonucleases. 
Single cell gel electrophoresis (SCGE) is a technique used for the detection of DNA damage. 
Originally developed and referred to as the Comet Assay (Ostling and Johanson, 1984), this 
method used neutral conditions and only permitted the detection of double strand DNA breaks 
(Rojas et ai., 1999). This method was subsequently modified by Singh et ai. (1988) in order 
to incorporate alkaline conditions. This ensures the detection of DNA double strand breaks 
and alkali labile sites, DNA-DNAIDNA-protein cross-linking, as well as single strand breaks 
associated with incompletely repaired excision in individual cells. The assay can be used with 
a variety of cell types and also has a wide variety of applications, such as genotoxicity and 
DNA repair studies, clinical applications and human and environmental monitoring (Rojas et 
ai., 1999). 
40 
DNA damage IS determined by exammmg the individual comets that form after 
electrophoresis. Briefly, cells, mixed with low-melting-point agarose (LMP A), are 
sandwiched between two layers of LMP A on a microscope slide. Cells are then placed in a 
lysis solution (a highly aqueous salt solution and detergent). The salt disrupts proteins and the 
bonding pattern within the cell, whilst the detergent (Triton X-I00) dissolves cellular 
membranes. Incubating samples in lysing solution ensures that only the DNA of the cell 
remains. Prior to electrophoresis, DNA unwinding is achieved by placing cell laden slides in 
an electrophoretic buffer (PH 13), and DNA starts to unwind from sites of strand breakage 
(Rojas et al., 1999; Tice et al., 2000). DNA that is damaged loses its compact structure and 
moves into the agarose matrix in an electric field. The negatively charged loose DNA moves 
towards the anode forming a comet-shaped image. The head of the comet represents the 
undamaged DNA, while the tail represents the damaged DNA. Comet tails are the result of 
the migration of relaxed DNA loops to a limited distance and the length of these loops 
determines the length of the comet tail (Zeljezic et al., 2006). 
The DNA can be viewed through the use of ethidium bromide (EtBr) staining 
(an intercalating dye). After excitation, red fluorescence is produced and individual cells may 
be examined. Fluorescence intensity and length is related to the number of DNA strand 
breaks induced by the test agent (McKelvey-Martin et aI., 1993). The parameter most 
commonly used to quantify DNA damage is the length of DNA migration (tail length) in 
micrometres (~m) (Rojas et ai., 1999). Migration length is directly related to fragment size 
and is expected to be proportional to the extent of DNA damage (Tice et al., 2000); therefore, 
longer tail lengths mean greater DNA damage. 
An advantage of using SCGE is that detection of DNA damage can be made at the level of the 
single cell and that only a small number of cells is required. Furthermore, almost any 
eukaryotic cell population can be used and the assay is able to evaluate DNA damage in 
non-proliferating cells (Rojas et al., 1999). This assay is sensitive, simple, cost-effective and 
data can be obtained within a few hours of sampling. 
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The aim of the work reported in this chapter was to assess the immuno-genotoxicity of OT A 
in male Wistar rats using SCGE. In addition, PBMCs from rats treated with S. frutescens and 
in combination with OT A were examined for genotoxicity. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Low melting point agarose (LMPA) was purchased from Whitehead Scientific (S.A.); Sodium 
chloride (NaCl), Ethylenediaminetetraacetic acid (EDTA), Tris, Dimethyl sulphoxide 
(DMSO), Sodium hydroxide (NaOH), Disodium ethylenediaminetetraacetic acid (Na2EDTA), 
Triton X-IOO and Ethidium bromide (EtBr) were obtained from Merck (S.A.); Slides and 
Coverslips were purchased from Shalom Laboratories (S.A.). All other reagents were 
obtained from Merck (S.A.). 
5.2.2 Methods 
Initially, 1 % LMP A (400IlI) (Appendix B 1) was dispensed onto a glass slide. This was 
immediately covered with a coverslip and allowed to set (10 min, 4°C), thereby forming a 
layer of agarose over the slide. After removing the coverslips, a mixture of rat whole blood 
(20IlI) and 0.5% LMPA (I80IlI) (Appendix BI) was added over the first layer, then allowed 
to set (20 min, 4°C). A final layer of 0.5% LMPA (200IlI) was added over the second layer. 
The third layer was allowed to solidify for ±20 min. The above steps were crucial since the 
agarose layer had to be fixed onto the slide in order for it to withstand the steps that followed. 
Subsequent to the removal of the coverslips, slides were placed in freshly prepared cold lysing 
solution (Appendix B2) (1 hr). 
Thereafter, slides were equilibrated (20 min) in the electrophoresis buffer (PH 13) 
(Appendix B3) to allow the DNA to unwind prior to electrophoresis. Following equilibration, 
the samples were electrophoresed (35 min, 300mA (25V)) to allow for the migration of DNA. 
42 
After electrophoresis, the agarose-Iayered slides were washed with O.4M Tris (PH 7.4) 
(Appendix B4) (3 washes for 5 min each). The washing procedure removes excess 
electrophoresis buffer and neutralises the gel. The slides were handled carefully in order to 
prevent any agitation of the agarose layers. Good drainage is important, as excess 
electrophoresis buffer could interfere with the EtBr staining and minimises background 
intensity on the slides. 
Finally, gels were stained with 40111 EtBr (20Ilg/ml). Images were viewed using an Olympus 
IXSI microscope. The Comet tail lengths in 50 randomly selected cells for each treatment 
were measured using the Analysis LS Research software. These steps were carried out under 
minimal light conditions. 
5.2.3 Statistical Analysis 
Statistical analysis was performed using GraphPad Instat v3.06 (GraphPad Software, San 
Diego, CA). Comparisons between treatments were made using One-Way Analysis of 
Variance (ANOVA). Significant differences were determined using Tukey-Kramer Multiple 
comparison tests. A probability value (P) of less than 0.05 (p<0.05) was considered 
statistically significant. 
5.3 RESUL TS AND DISCUSSION 
One of the hallmarks of the advanced stages of apoptosis is DNA fragmentation. Since the 
measurement of a comet tail length is related to DNA fragmentation (single strand breaks), 
the tail lengths can be used as a measure of apoptosis. 
Cells undergoing apoptosis and necrosis can be distinguished from one another based on the 
characteristics of the comets produced. Apoptotic cells can be recognised by a small comet 
head and a long fan-like tail and most of the DNA migrates out of the nucleus. This sets it 
apart from healthy cells where most of the DNA remains intact within the nucleus. Necrotic 
cells (double stranded DNA breaks), however, are characterised by a non-dense, large comet 
head and a shorter, narrow tail. 
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The analysis of the SCGE photomicrographs shows that the pre-treatment groups (Day 0) 
produced no DNA damage (Fig. 5.1a-d). In the control group, cells retained a dense nuclear 
stain and showed minimal comet length variations between Day 0 to Day 7 (Fig. 5.1a-i). The 
control group treatments contained ethanol, which had minimal effects on rat PBMC DNA 
damage. 
A gradual duration-dependent increase in comet tail length was noticed in the S. frutescens rat 
group (Fig. 5.1 and Fig. 5.2). The longest tail length was produced by S. frutescens-only at 
Day 7 (Fig. 5.1j) and the tail length was significantly longer when compared with the control 
for the same period (P<O.OOl). The presence of long tail lengths are strong indicators of 
apoptosis in the immune cells. 
Previous studies on cultured cells showed that S. frutescens possessed apoptotic inducing 
abilities (Tai et aI., 2004; Chinkwo, 2005). The study by Chinkwo (2005) demonstrated that 
S. frutescens produced similar DNA fragmentation patterns as compared to known inducers of 
apoptosis, such as ceramide. Ceramide can indirectly activate caspases which leads to 
induction and increased caspase-3 activity that results in the activation of endonucleases and 
DNA fragmentation (Selzner et aI., 2001). Thus, S. frutescens seems to have a similar action 
on DNA fragmentation and apoptosis. 
Sutherlandia frutescens is widely known for its use as an anti-tumour agent and the 
compounds present in S. frutescens are believed to work together to perform this function. 
Among the plant's active ingredients, L-CA V is believed to be a potent anti-tumour agent. A 
study by Hare (1969) showed that L-CA V can induce alterations in the nuclear architecture of 
mammalian cells. These alterations were characterised by the formation of irregular 
aggregates of nucleoplasmic contents attached to the nuclear membrane. The authors 
proposed that L-CA V was able to induce such an effect as a result of the formation of 
canavanyl protein-DNA aggregates. 
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Figure 5.1: Photomicrographs showing comet formation on Days 0, 1 and 7. 
The persisting presence of L-CA V may result in cell death (Akaogi et al., 2006). A study 
using human lurkat cells, conducted by lang et al. (2002), showed that L-CA V increased the 
sub-G 1 phase, which represents apoptotic cells, in a dose dependent manner. The authors 
concluded that L-CA V -induced apoptotic DNA fragmentation accompanied the activation of 
caspase-3. 
Furthermore, it is believed that L-CA V competes with L-ARG cellular enzymes, such as 
iNOS and arginase (Akaogi et al., 2006). Subsequently, L-CA V may disrupt biochemical 
pathways involving L-omithine since arginase facilitates the hydrolysis of L-ARG to 
L-omithine, which is a precursor of polyamines (Bence et a!., 2002). It is known that 
polyamines (organic cations of low molecular weight) promote cell growth and that if 
polyamine synthesis is inhibited then cell growth is stopped. As a result of their polybasic 
character, polyamines adhere strongly to nucleic acids, thereby stabilising DNA by 
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neutralising the negative charges of the phosphate groups and decreasing the repulsion 
between the strands of DNA (Yerlikaya, 2004). Studies have shown that polyamine-depleted 
cells undergo changes in chromatin and DNA structure (Berger et ai. , 2007). Furthermore, 
histone acetylases and deacetylases, which influence histone function, are regulated by gene 
promoters and inhibitors, which, in tum, are controlled by polyamines (Criss, 2003). Thus 
polyamines play a vital role in the maintenance of genome integrity, and disruptions in 
polyamine homeostasis may result in decreased polyamines, which may severely affect DNA 
structure and integrity. Thus, L-CA V may alter DNA integrity as a result of its inhibitory 
effect on arginases and subsequent effects on L-omithine and polyamine synthesis. 
In addition, GAB A may also act as an anti-tumour agent, which may prevent metastasis in 
vivo (Tai et ai. , 2004). Also, the triterpenoids present in the leaves of S. frutescens may 
possess apoptotic-inducing abilities (Kikuchi et ai. , 2007; van Wyk and Albrecht, 2008). 
Observation of the OT A-treated rat PBMCs revealed that the comet tail lengths increased 
after 1 day and was significantly longer than that of the control (1 day) (p<0.01). However, a 
slight decrease in tail lengths was noted after the 7-day OTA treatment (Fig. 5.1i-1 and 5.2). 
Also, tail lengths of the OT A and S. frutescens combination group at Day 7 were significantly 
shorter than that of the S.frutescens-only group for the same period (p<0.001). 
The co-treatment with S. frutescens after 7 days resulted in a slight increase in DNA damage, 
however not significant. Shorter tail lengths were produced by the Day 1 co-treatment 
compared with the OT A treatment for the same duration. It is possible that S. frutescens may 
have delayed the onset ofOTA-induced DNA damage (Fig. 5.2). 
Ochratoxin A demonstrated the capacity to induce DNA damage in target as well as 
non-target organs, such as the kidney, liver, spleen and peripheral lymphocytes 
(Mally et ai., 2005; Kamp et ai. , 2005). It is evident from this, as well as from a previous 
study (Mally et ai., 2005), that OTA may induce DNA damage in immune cells. A study by 
Seegers et al. (1 994b ) demonstrated that OTA treatment resulted in apoptosis-associated 
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Group 4 - OT A and S. frutescens 
Figure 5.2: A measure of DNA damage by single cell gel electrophoresis in blood taken from 
male Wistar rats on Days 0, 1 and 7 (n=4). Values represented as mean ±SEM. * indicates 
comparison with the control for the same periods of time **p<O.Ol ***p<O.OOl. * indicates 
the comparison between S. frutescens-only and combination treatment ***p<O.OOl. 
If DNA damage is minor then repair mechanisms become active, however, apoptosis is 
induced if DNA damage is severe. An unregulated growth of cells may however result if 
apoptosis is not activated, leading to the formation of tumours that may be cancerous. The 
decrease in rat PBMC comet tail length at Day 7 may be indicative of an increase in DNA 
repair mechanisms. It is also possible that fewer viable cells were available (Mally et ai. , 
2005), since many cells may have succumbed to OTA toxicity. It has also been proposed that 
the biotransformation of OT A may lead to the production of reactive intermediates 
(Ringot et ai., 2006). These intermediates may lead to the formation of DNA adducts, thereby 
resulting in DNA damage. 
Oxidative stress is believed to be one of the factors that induce OT A toxicity. The differences 
in DNA damage could possibly therefore be attributed to oxidative stress. This response may 
occur if the antioxidant system is inefficient and therefore reactive intermediates or free 
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radicals (ROS) are not detoxified. Subsequently, these reactive species can target DNA, 
resulting in DNA damage. Schaaf et al. (2002) and Mally et al. (2005) suggested that DNA 
damage from OT A toxicity could be due to oxidative stress. This oxidative stress may be a 
result of disruptions in the mitochondrial electron transport chain. 
Furthermore, OT A is a known disruptor of mitochondrial function ; it was shown that OTA 
caused DNA damage in vitro by forming 8-oxoguanine (an oxidative DNA damage product) 
(Schaaf et ai., 2002; Arbillaga et al. , 2007a). It is reasonable to assume that in the present 
study OT A caused disruptions in mitochondrial function leading to increased oxidative stress. 
This increased oxidative stress could be responsible for the rat PBMC DNA damage. This 
has subsequently brought about the debate concerning DNA-reactive and DNA-non-reactive 
mechanisms for DNA damage due to the presence ofOTA (Gautier et al., 200Ia; Marin-Kuan 
et al. , 2006; Marin-Kuan et al. , 2008). The present study indicates that OTA induces DNA 
damage in rat immune cells, which was significant after a I-day treatment. 
5.4 CONCLUSION 
The control did not show any changes in DNA damage. The comet tail lengths of the 
S. frutescens-only treatment increased with the duration of time. In addition, the longest tail 
lengths were produced by the S. frutescens-only treatment after 7 days. Since SCGE is used 
as a measure of apoptosis, it is possible that the apoptotic-inducing agents present In 
S. frutescens may have caused the increase in comet tail length observed on Day 7. 
The present study indicates that OT A produces a degree of DNA damage in immune cells. 
After a period of 7 days, however, the tail lengths diminished, which is indicative of a 
decrease in DNA damage. It was noted that a combination of S. frutescens and OT A may 
delay the onset of DNA damage. The observed changes in DNA damage may be due to 
apoptosis rather than necrosis as indicated by the shape of the Comet tails. 
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CHAPTER 6 
FLOW CYTOMETRIC ANALYSIS OF APOPTOSIS AND 
MITOCHONDRIAL MEMBRANE POTENTIAL IN LYMPHOCYTES 
OF OCHRATOXIN A TREATED MALE WISTAR RATS 
6.1 INTRODUCTION 
Cell death occurs by two mechanisms, i.e., apoptosis and necrosis. Apoptosis, known as 
programmed cell death, is a programmed transition from an intact metabolically active state 
into a number of shrunken apoptotic bodies (Hotchkiss and Nicholson, 2006). In contrast, 
necrotic death is a passive form of cell death and is characterised by the swelling and rupture 
of injured cells, resulting in inflammation. Whereas necrosis does not require energy, 
apoptosis is an ATP requiring process (Rastogi et aI. , 2009) . 
Mitochondria are organelles involved in major metabolic pathways, however, cells 
undergoing apoptosis are characterised by a disruption in mitochondrial physiology. During 
apoptosis, mitochondrial permeability is altered resulting in the release of cytochrome c from 
inside the mitochondria to the cytoplasm (Heiskanen et al., 1999). Cytochrome c release is 
also coupled with the depolarisation of the mitochondrial membrane and caspase activation 
(Heiskanen et al., 1999; Kroemer et aI. , 2007). 
Apoptosis can be detected through characteristic morphological cell changes. These changes 
include: exposure of phosphatidylserine on the external side of the cell membrane, 
fragmentation of DNA, aggregation of chromatin and the creation of apoptotic bodies. Flow 
cytometry is widely used to detect the morphological changes characteristic of cells 
undergoing apoptosis. 
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6.1.1 Flow Cytometry 
Flow cytometry is a technique used for making rapid measurements on particles or cells as 
they flow in a fluid stream one at a time through a laser beam (Ormerod, 2000). Cells are 
sorted into different populations using fluorescence-activated cell sorting (F ACS) (Fig. 6.1). 
The advantages of flow cytometry are that measurements are made on individual cells and 
multiple cellular parameters can be measured. It is easier to process body fluids as compared 
with solid tissues. Blood contains individual cells that can be stained and processed directly 
on the flow cytometer. Solid tissues, however, are not easy to process, because enzymatic 
digestion and detergents may be required for the preparation of some tissues and organelles 
(Ormerod, 2000). 
6.1.1.1 Fluidics, Optics and Electronics 
A flow cytometer comprises three functional systems, viz., fluidics, optics and electronics 
(BD Biosciences, 2000). Measurements are made based on a particle's relative size, internal 
complexity and relative fluorescence intensity (Ormerod, 2000). The fluidic system delivers 
particles/cells of a fluid stream, singly, to a particular point that is intersected by an 
illuminating beam. Therefore, flow cytometric tubes containing cells are placed in the centre 
of an enclosed chamber through which the sample flows into a flowing stream of sheath fluid 
(BD Biosciences, 2000). Particles are restricted to the centre of the fluid stream by a process 
referred to as hydrodynamic focussing (BD Biosciences, 2000). 
Light from each particle that is passed through the laser beam is captured. Thus an optical 
system is also incorporated into the flow cytometer and it consists of excitation optics and 
collection optics (BD Bioscience, 2000). In order to produce specific wavelengths, the light 
source has to be efficient and intense, as measurements are made based on light as a source of 
excitation. Thus the (argon) laser beam is used and the illumination source is part of the 
excitation optics (Ormerod, 2000). 
As the cell passes through the laser beam, it scatters light at all angles. Forward scatter (FSC) 
refers to the emission of light in a forward direction and this is dependent upon particle size, 
therefore different cell populations can be distinguished from one another (Rahman, 2006). 
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Side scatter (SSe) describes light that is scattered in a perpendicular direction. This type of 
light scatter is dependent on the number of organelles inside the cell (Rahman, 2006) and if 
few organelles are present in the cell, then side scatter is low. 
Fluidics system 
Figure 6.1: Illustration showing flow cytometer instrumentation. Suspensions are passed 
through the fluidics system and the light scattered by cells is collected by photodetectors. 
Signals are digitised and passed on to the computer for display and analysis (Rahman, 2006). 
The conjugation of fluorescent dyes to ligands and to polyclonal and monoclonal antibodies 
can be used in determining specific aspects of a cell, such as cell surface and cytoplasmic 
factors (Ormerod, 2000). Also, the ability of different compounds to fluoresce at different 
wavelengths enables several parameters to be analysed. The scattered and fluorescent light 
generated by cells passing through the illuminating beam is collected by photodetectors via 
dichroic mirrors and optical filters (bandpass and shortpass filters). This makes up the 
collection optics (BD Bioscience, 2000). Thereafter, fluorescence and side scattered signals 
are diverted to the photomultiplier tubes (PMT) and forward scattered signals are diverted to 
the photodiode (Rahman, 2006). 
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Photodetectors convert photon pulses into electronic signals. The analogue to digital 
converter (AD C) allows the electrical pulses to be digitised so that data may be displayed on a 
computer. Electronic and computational processing results in a graphic display which can 
then be analysed (Ormerod, 2000). 
6.1.1.2 Graphical Display 
The most common and useful way of display is through frequency histograms and dual 
parameter plots, also known as dot/scatter plots. The frequency histogram is a direct 
representation of the number of events occurring for each channel of the ADC. Dot plots are 
a 2-dimensional representation of the frequency histogram and FSC and SSC parameters for a 
particular sample are used to obtain the histogram. The FSC and SSC differ between cells 
and particles, and thus the biochemical, biophysical and molecular properties can be studied 
(Ormerod, 2000). 
6.1.2 Flow Cytometric Detection of Apoptosis and Necrosis 
In the early stages of apoptosis, the translocation of negatively charged phosphatidylserine 
(PS) from the internal to the external cell membrane takes place (Fig. 6.2). This allows for 
the detection and rapid phagocytosis of the cells. 
Annexin V is a protein that binds in a Ca2+ -dependent manner to PS (Fig. 6.2) and therefore, 
serves as an excellent probe to detect apoptotic cells (Ormerod, 2000). Annexin V will not 
bind to healthy cells. Since necrotic cells also contain PS, apoptotic cells must be 
differentiated from necrotic cells. This is done by using a vital dye such as propidium iodide 
(PI) which only stains cells with disrupted cell membranes (Ormerod, 2000), since it is not 
membrane-permeable. In flow cytometry, Annexin V is conjugated to fluorescein 
isothiocyanate (FITC) (Vermes et ai. , 1995), which possesses an excitation wavelength of 
488nm and emits light signals at wavelength 518nm. Since the morphology of apoptotic and 
necrotic cells are different, forward and side scatter properties of the cell can be used to 
identify apoptotic from necrotic cells. 
52 
Annexin V 
Outer Cell Membrane 
Inner Cell Membrane 
Phosphatidylserine Other Phospholipids Annexin V 
Figure 6.2: Illustration of phosphatidylserine flipping during apoptosis and the subsequent 
binding of Annexin V to phosphatidylserine (Trevigen, 2007). 
6.1.3 Mitochondrial Membrane Depolarisation Detection 
A prominent characteristic of apoptosis is the change in mitochondrial membrane potential 
(~'Pm) (Kroemer et aI. , 2007). Energy released during oxidation reactions in the 
mitochondrial respiratory chain is stored as a negative electrochemical gradient across the 
mitochondrial membrane and the membrane potential is referred to as being polarised. 
However, during apoptosis there may be a collapse in ~ 'Pm, which results in depolarised 
mitochondria (Kroemer et ai. , 1997). Mitochondrial depolarisation is often used as an 
indicator of apoptosis. 
JC-I (5,5', 6,6'-tetrachloro-l , 1', 3,3' -tetraethylbenzimidazolcarbocyanine iodide) is a 
membrane-permeable lipophillic cationic fluorochrome that is used to measure ~ 'Pm 
(Ormerod, 2000). JC-l is excited using a wavelength of 488nm. The fluorescence emission 
spectrum is dependent on its concentration, which in turn is determined by the status of the 
~ 'Pm. JC-I can occur as aggregates or monomers, each with different emission spectra: 
527nm and 590nm respectively (BD Biosciences, 2003). While aggregates form at high dye 
concentration, monomers form at low concentrations. Both exhibit green fluorescence, but 
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JC-l aggregates show a red spectral shift (BD Biosciences, 2003). JC-l selectively enters 
mitochondria and changes colour from green to red as the membrane potential increases. 
Thus, in healthy cells, mitochondria are polarised and JC-l is rapidly taken up, forming JC-l 
aggregates and a higher red fluorescence emission (Fluorescence (FL)-2 channel). JC-l does 
not accumulate in apoptotic (unhealthy) cells with depolarised mitochondria and it remains in 
the cytoplasm as monomers (green fluorescence) (BD Biosciences, 2003). 
The aim of the study reported in this chapter was to determine the apoptotic potential of OT A 
and S. frutescens on rat lymphocytes. 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Annexin-V-FLUOS staining kit was purchased from Roche Diagnostics (Penzberg, 
Germany); BD ™ MitoScreen Kit was obtained from Becton Dickinson, BD Biosciences 
(San Jose, CA). All other reagents were obtained from Merck (S.A). 
6.2.2 Methods 
Peripheral blood mononuclear cells (PBMCs) were isolated by differential centrifugation, as 
discussed in Chapter 3. 
6.2.2.1 Flow Cytometric Analysis of Peripheral Blood Mononuclear Cells - Sample 
Preparation 
Initially, an aliquot of (l001l1) PBMCs (lxl06cells/ml) was transferred to appropriately 
labelled polystyrene flow cytometric tubes and pelleted by centrifugation (5 min, 200xg). 
Pellets obtained were re-suspended in the appropriate labelling solution (Annexin-V -FLUOS 
or JC-l) 
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6.2.2.2 Staining of Peripheral Blood Mononuclear Cells 
6.2.2.2a Annexin V-FLUOS/Propidium Iodide 
Annexin-V-FLUOS labelling solution was prepared by diluting the Annexin-V-FLUOS 
labelling reagent (20J.lI) and the PI solution incubation buffer (lml). 
The pellet obtained (in 6.2.2.1) was re-suspended in 100j...l1 Annexin-V -FLUOS reagent and 
incubated in the dark (15 min, RT). The Annexin reagent is light-sensitive, therefore, 
procedures were carried out under minimal light exposure. 
6.2.2.2b Mitochondrial Membrane Potential - JC-l 
The pellet (in 6.2.2.1) was re-suspended in freshly prepared JC-l working solution (500j...l1). 
Tubes were vortexed thoroughly to eliminate any cell-to-cell clumping and then incubated in 
a CO2 incubator (15 min, 37°C). After the required time period, stained PBMCs were washed 
with JC-l MitoScreen wash buffer (2ml) (5 min, 400xg, RT). 
6.2.2.3 Instrumentation and Analysis of Samples 
Both Annexin-V-FLOUS and JC-l data were analysed using a FACSCalibur flow cytometer. 
Prior to analysis, an incubation buffer (500j...l1) was added to each sample of stained PBMCs. 
Tubes containing the sample were then gently shaken and placed into the flow cytometer. 
Analysis of all samples was conducted using an excitation wavelength of 488nm. 
Subsequently, FLI (Annexin-V-FITC-PS) and FL3 (propidium iodide-DNA) signals were 
detected via 515nm and 600nm bandpass filters respectively. Similarly, JC-l monomers were 
detected at 527nm and JC-l aggregates at 590nm. 
6.2.2.4 Data Analysis 
Data was acquired with Cell Quest PRO v4.0.2 software (BD Biosciences) and analysed using 
FlowJo v7.1 Software (Tree Star, Inc.). Analysis was carried out using scatter/density plots. 
Initially, the total lymphocyte population was distinguished from the heterogeneous 
population and debris by using the forward and side scatter parameters of the lymphocyte 
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profile. Thereafter, lymphocytes were gated on their respective fluorescent probes for the 
respective assays. Regarding the Annexin stained samples, the lymphocyte population was 
gated at the 102 mark on the FL1 and FL3 channels creating cluster gates, thereby 
differentiating apoptotic and necrotic PBMCs. Apoptotic PBMCs were Annexin-V-FITC 
positive (x-axis) but PI negative (y-axis) (bottom right quadrant) and necrotic PBMCs were 
positive for both Annexin-V-FITC and PI (top right quadrant) (Fig. 6.3 and Fig. 6.4). 
Since JC-1 monomers and aggregates show fluorescence in both the FL-1 and FL-2 channels, 
lymphocytes were gated on these channels and were thus recognised as having polarised or 
depolarised mitochondria (Fig. 6.5). FL-1 bright and FL-2 bright were indicative of healthy 
cells, with polarised mitochondria. A decrease in the FL-2 channel, where the FL-1 remains 
high, is indicative of cells with mitochondrial depolarisation. 
6.2.3 Statistical Analysis 
Flow cytometric data was analysed on GraphPad Instat v3.06 (GraphPad Software, San 
Diego, CA). Comparisons between the treatments were made using One-Way Analysis of 
Variance (ANOVA) and the Tukey-Kramer Multiple comparisons test. A probability value 
(P) of less than 0.05 (p<0.05) was considered statistically significant. 
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6.3 RESULTS AND DISCUSSION 
Cell signalling is responsible for the regulation of apoptosis, such that only those cells 
destined for cell death will die. Therefore, inconsistencies in apoptosis may be attributed to 
alterations in cell signalling. The lymphocyte population consists of T cells, B cells and 
natural killer cells. These cells play an important role in the immune system and in the 
defence against intruders in the body. If the number of lymphocytes decreases, then the 
immune function becomes compromised, and this may increase the susceptibility to various 
infections. 
The Annexin-V-FLUOS assay differentiates apoptotic from necrotic cells (Table 6.1). After 
flow cytometric analysis, it was observed that the I-day OTA-only treatment resulted in a 
2.08-fold increase in apoptotic lymphocytes (15%) when compared to the control (7.2%) 
(p<0.01) (Table 6.1 and Fig. 6.3). There was also a 5-fold increase in necrotic lymphocytes 
compared to the control (Day 1). Furthermore, the 7-day OTA treatment resulted in a 
1.22-fold increase in apoptotic lymphocytes (10.1 %), but a decreased (1.64-fold) amount of 
necrotic lymphocytes, compared to the respective controls (Table 6.1). 
Table 6.1: Quantification of apoptotic and necrotic lymphocytes represented by the 
mean ±SEM (n=4). **p<O.Ol. 
Treatment Duration Apoptotic (%) Necrotic (%) 
Control 1 day 7.2±2.15 0.2±O.10 
S.yrrutescens-only 11.7±2.39 0.1±0.05 
OTA-only 15±0.49** I±O.16 
OT A and S. yrrutescens 13.2±O.12 1.4±0.22 
Control 7 days 8.3±0.75 0.2±0.00 
S. frutescens-only 9.7±0.79 0.2±0.05 
OTA-only 10.1±0.62 O.1±0.08 
OT A and S. yrrutescens 12.7±0.94 0.0±0.01 
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Petrik et al. (2003) demonstrated, in a study on male Wistar rats, that OTA treatment can 
cause an increase in the number of cells undergoing apoptosis in both distal and epithelial 
kidney cells. According to AI-Anati and Petzinger (2006), OTA-induced apoptosis is not 
limited to the urinary tract but is also found in the immune system. In relation to other 
studies, OTA demonstrated the capacity to increase apoptosis in PBMCs (Seegers et al. , 
1994b; Schwerdt et al. , 1999; Gekle et al., 2000; Assaf et ai. , 2004). In the study by Assaf et 
al. (2004), PBMCs were isolated from healthy donors and then treated with OTA after PBMC 
separation. This was different from the present in vivo study in which rats were initially 
treated with OT A. Results of that study showed that apoptosis was induced due to a decrease 
of Bcl-XL (anti-apoptotic protein) and a disruption of mitochondrial function. 
A comparison between the OT A Day 1 and Day 7 regimes indicated that there was a 1.48-fold 
decrease in the amount (10.1 %) of apoptotic lymphocytes and 9.10-fold decrease in necrotic 
lymphocytes (0.1 %) on Day 7 (Table 6.1 , Fig. 6.3 and Fig. 6.4.). Thus, the results suggest 
that OT A toxicity may be influenced by the duration of time the toxin is in the body. The 
decrease in apoptotic and necrotic lymphocytes may be due to the fact that this study was 
conducted in vivo, thus, if there were disruptions in biochemical pathways, the body may have 
reacted to it. Similarly, this could explain the difference in the number of necrotic 
lymphocytes after 1 day (1 %) and 7 days (0.1 %). Also, the type of cell death stimulated by 
OT A may be determined by dose and exposure time (AI-Anati and Petzinger, 2006). The 
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Figure 6.3: Scatter plots showing apoptotic (bottom right quadrant) and necrotic (top right 
quadrant) rat lymphocytes after Day 1: A) Control; B) S. frutescens-only; C) OT A-only; 
D) OTA and S.frutescens. 
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Flow cytometry showed that the Day 1 S. frutescens treatment increased (1.62-fold) the 
percentage of apoptotic lymphocytes (11.7%) compared to the control (Table 6.1 and 
Fig. 6.3). In contrast, there was a 2-fold decrease in the amount of necrotic lymphocytes 
(0.1 %) compared to the control (Table 6.1). Chinkwo (2005) confirmed that S. frutescens can 
induce apoptosis in CHO, Caski and Jurkat cells. In that study several morphological features 
associated with apoptosis were detected, such as PS externalisation, chromatin condensation 
and DNA fragmentation. In addition, the present study also demonstrated 
apoptosis-associated DNA fragmentation induced by S. frutescens (Chapter 5). Furthermore, 
gene expression profiles on MCF-7 cells showed that a number of genes required and 
considered important for apoptosis were expressed after S. frutescens treatment (Stander et 
ai., 2007). 
The phytocompounds present in S. frutescens may contribute to the observed increase in 
apoptosis (Tai et ai., 2004). L-canavanine has been shown to possess apoptotic activity 
(Jang et ai., 2002; Akaogi et ai. , 2006). In a study by Jang et ai. (2002), flow cytometric 
analysis revealed that the sub-G 1 phase, which represents apoptotic cells, increased in a 
dose-dependent manner. Furthermore, L-CA V may also facilitate the shrinkage of tumour 
growths, in mice and rats (Green et ai. , 1980; Thomas et ai., 1980). 
Nitric oxide synthase produces nitric oxide (NO) from L-ARG. Since L-CA V is an L-ARG 
analogue, L-CAV can replace L-ARG, thereby inhibiting NO synthesis (Akaogi et ai. , 2006). 
S-nitrosylation is a biochemical process that involves the reversible coupling of NO to a 
reactive cysteine thiol, forming molecules referred to as S-nitrosothiols, which modulate 
protein function (Iyer et at., 2008). Nitric oxide may inhibit apoptosis through S-nitrosylation 
of various proteins involved in the apoptotic cascade, such as caspase-8, -9 and -3, cFLIP, 
Bcl-2 and protein kinase C (PKC) (Dash et ai. , 2007; Iyer et al., 2008). Thus, if L-CA V is 
substituted in place of L-ARG, NO synthesis will decrease, resulting in S-nitrosylation 
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Figure 6.4: Scatter plots showing apoptotic (bottom right quadrant) and necrotic (top right 
quadrant) rat lymphocytes after Day 7: A) Control; B) S. frutescens-only; C) OTA-only; 
D) OTA and S.frutescens. 
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Furthennore, the major triterpenoids present in S. frutescens are structurally related to 
cycloartane-type triterpenoids which possess proven cancer chemopreventive activity 
(Kikuchi et al., 2007). Flavonoids, contained in the plant, induced apoptosis in cancer cells 
(Zhang et aI., 2008). Thus it is possible that flavonoids may also be responsible for the 
apoptotic activity in S. Jrutescens. In light of the above, although L-CAV may be a major 
inducer of apoptosis, other compounds found in the plant may also play a pivotal role, thus 
increasing apoptosis. 
After the 7-day s.Jrutescens treatment, the Annexin-V-FLUOS assay showed that there was a 
1.2l-fold decrease in apoptotic lymphocytes (9.7%) but a 2.40-fold increase in necrotic 
lymphocytes (0.2%), when compared to the I-day regime (Table 6.1). Necrosis may be 
induced when there is an excess of ROS or when the antioxidant systems are disturbed 
(Proskuryakov et al., 2003). Furthennore, L-CAV may result in oxidative stress (Riganti et 
al., 2003), which may then have resulted in the increase in necrotic lymphocytes noted after 
the 7 -day S. Jrutescens treatment. 
Rats were also treated with a combination of S. Jrutescens and OT A. When compared to the 
respective controls, both Day 1 (13.2%) and Day 7 (12.7%) co-treatments showed an increase 
in apoptotic lymphocytes (Table 6.1). However, a 1.04-fold decrease in the number (12.7%) 
of apoptotic lymphocytes was observed after the 7-day combination treatment in comparison 
to the Day 1 combination group (13.2%). 
When compared to the Day IOTA-only rat group, the combination treatment (Day 1) showed 
an antagonistic decrease (1.l4-fo1d) in lymphocyte apoptosis and a 1.40-fo1d increase in the 
amount of necrotic lymphocytes (Table 6.1). In contrast, co-treatment after a 7-day period 
produced a 1.25-fold increase in apoptotic lymphocytes in comparison to the OTA-treated rat 
lymphocytes, for the same duration. Also, flow cytometry suggests that after the 7 -day 
combination regime necrotic lymphocytes were very few to none (Table 6.1). These results 
highlight the apoptotic potential of the combination of S. Jrutescens and OT A after an 
extended period in the body. 
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The JC-l assay is used to determine mitochondrial depolarisation, which is an indicator of 
apoptosis. After analysis of the JC-l assay (Fig. 6.6), it was evident that, on Day 1, the 
S. frutescens treatment resulted in a significantly higher percentage of lymphocytes (61.6%) 
with depolarized mitochondria than the control (11.7%) (p<0.001). However, after 7 days, 
S. frutescens treatment exhibited a significant decrease (12.2%) in mitochondrial 
depolarisation compared to the Day 1 S. frutescens treatment (p<0.00 1). The high percentage 
of lymphocytes with depolarised mitochondria may be a result of the apoptosis-inducing 
ability S. Jrutescens. GABA, a weak acid present in S. Jrutescens, may disrupt the proton 
gradient of mitochondria and alter mitochondrial polarity. The proton gradient is used to 
drive the synthesis of A TP. Therefore, GAB A may be one of the reasons for the increase in 
the percentage of cells with depolarised mitochondria. In addition, L-CA V is considered to 
be a potent anti-cancer agent and may affect mitochondrial function. 
On Day 7 there was a significant increase in the number of lymphocytes (56.5%) showing 
mitochondrial depolarisation in the OTA-only treated rats compared to the control (6.8%) 
(p<0.001) (Fig. 6.6). When compared to the Day IOTA rat group, a significant 
time-dependent (3.71-fold) increase in depolarisation was noted (p<0.001). Thus, as 
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Figure 6.5: An example of a scatter plot of rat lymphocytes stained with JC-l dye, depicting 
polarised and depolarised lymphocytes. 
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It has been proposed that OTA treatment may result in disruptions in mitochondrial function 
and that this may occur as early events of toxicity (Aleo et al., 1991; Bouaziz et aI., 2008). 
According to Wei et al. (1985), OT A is believed to affect mitochondrial respiration and 
oxidative phosphorylation through the succinate-support electron transfer activities of the 
mitochondrial respiratory chain. There could subsequently be set-backs in the electron 
transport chain, resulting in the disruption of mitochondrial function. This may therefore have 
led to the mitochondrial depolarisation that was observed in the present study. In a study by 
Assaf et al. (2004), OT A treatment of human PBMCs also resulted in a decrease in /!). 'Pm. It 
was also suggested that acute and chronic toxicity by OT A is either directly or indirectly 
related to the inhibition of transport carrier proteins located in the inner membrane of 























Group I Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 
Treatment 
Group I - Control Day I 
Group 2 - S. Jrutescens-only Day I 
Group 3 - OT A-only Day I 
Group 5 - Control Day 7 
Group 6 - S. Jrutescens-only Day 7 
Group 7 - OT A-only Day 7 
Day 1 
Day 7 
Group 4 - OT A and S. Jrutescens Day I Group 8 - OT A and S. Jrutescens Day 7 
Figure 6.6: Effect on mitochondrial membrane depolarisation after Ochratoxin A and 
Sutherlandia frutescens treatment. Data represent the mean ±SEM (n= 4). * indicates 
comparison between treatments and control **p<O.OI, ***p<O.OOl. * represents comparison 
between Day 1 and Day 7 regimes **p<O.Ol , ***p<O.OOl. 
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In addition, it is known that glutamine serves as a major fuel for immune cells, such as 
lymphocytes (Mates et ai. , 2002). Glutamine metabolism (glutaminolysis) results in the 
production of glutamate (Newsholme et ai. , 2003), which is a crucial substrate for 
mitochondrial respiration. Glutamate may be transaminated to a-ketoglutarate, an 
intermediate in the TCA cycle. Since glutamine is an important source of energy in 
lymphocytes, if glutamine metabolism is disrupted, then the supply of key components such 
as a-ketoglutarate may decrease. This would alter the TCA cycle and therefore energy 
production (ATP) would be reduced. It is thus possible that the observed changes in /). 'I'm in 
the present study could be attributed to alterations in glutamine metabolism. 
This means that the metabolic activity in cells will decrease and that cell viability will 
therefore decrease. Alterations in /). 'I'm may also lead to an inhibition of A TP synthesis. A 
comparison can be made with the PBMCs tested in chapter 4 (Fig. 4.1). It was observed that 
after a 7 -day OT A treatment, cell viability significantly decreased. This further points out 
that OT A produces cellular toxicity by disrupting mitochondrial activity. In addition, a 
decreased ATP level will alter other ATP-dependent processes, which may mediate 
immunotoxicity. 
The depletion of ATP reserves deprives the endoplasmic and plasma membrane Ca2+ pumps 
of fuel, causing an elevation of Ca2+ in the cytoplasm. There would subsequently be an influx 
of Ca
2
+ into the mitochondria, which would result in a decrease in mitochondrial membrane 
potential (Cribb et at., 2005) and a decrease in ATP. Thus it is possible that OTA may have 
caused a disruption in calcium in the cell. 
Disruptions in electron transport may result in an increased production of ROS. Opening of 
the PTPC can be triggered by several factors, one of them being ROS, which causes a sudden 
permeability ofthe inner mitochondrial membrane (Skulachev, 1996; Desagher and Martinou, 
2000). It is believed that increased ROS in the presence of Ca2+ causes cross-linking of 
mitochondrial protein thiols, which facilitates the opening of the PTPC (Fagian et ai., 1990). 
Thus OT A may have caused an increase in ROS in lymphocytes, which may in tum have 
triggered mitochondrial depolarisation. Other studies have indicated that OT A may cause 
oxidative stress (Gautier et at. , 2001 b; Boesch-Saadatmandi et at. , 2008). 
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The regulation of pro-and anti-apoptotic signals is important since it ensures that only 
necessary apoptosis takes place (Kroemer et al., 2007). The Bcl-2 family of proteins playa 
significant role in the permeability of the outer mitochondrial membrane and in the regulation 
of cell death. In the presence of cell death-promoting proteins (Bax and Bad), cytochrome c' 
is released from the mitochondrion, followed by the depolarisation of mitochondria and, 
subsequently, apoptosis. In this regard, it is possible that OT A may have caused defects in 
pro- and anti-apoptotic signals. 
A study by Arbillaga et al. (2007b) showed that, while there was an up-regulation of genes of 
the mitochondrial electron transport chain, genes associated with apoptosis were 
down-regulated. In the context of that study, the observed significant increase in the 
percentage of lymphocytes with depolarised mitochondria (OTA-only Day 7) (Fig. 6.6) but 
low apoptosis (Table 6.1) could be related to those factors. Also, looking back at the SCGE 
results (Chapter 5), it was observed that on Day 7 no significant difference was obtained 
between comet tail lengths of the OTA-treated rat group and the control (Fig. 5.2), which may 
indicate a lack of apoptosis. 
After 1 day, the combination of S. Jrutescens and OTA resulted in a higher percentage (23%) 
of lymphocyte mitochondrial depolarisation when compared to the control (p<0.01). 
Interestingly, a 7-day combination regime (Fig. 6.6), produced a 9.71-fold increase in 
lymphocyte mitochondrial depolarisation (66.2%), which was significantly different from the 
control over the same duration (p<0.001). Incidentally, a significant time-dependent increase 
(2.88-fold) in lymphocyte depolarisation was also noted after co-treatment (p<0.01). Thus the 
co-treatment may have resulted in a synergistic effect on lymphocyte mitochondrial 
depolarisation. This may have occurred since both OTA and S. Jrutescens disrupt 
mitochondrial function. 
Disruptions of the ~",m occur before cells exhibit DNA fragmentation or before the exposure 
of PS on the outer membrane leaflet (Kroemer et al. , 1997). It is possible for this reason that, 
significant results were acquired from the JC-1 assay, but not from the Annexin-V-FLUOS 
assay. Al-Anati and Petzinger (2006) have indicated that OTA-mediated immunotoxicity 
may occur by non-specific cell destruction, such as an interference with the cell's energy 
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supply. In accordance with this and other studies (Wei et ai., 1985; Petrik, et ai., 2003; 
Bouaziz et ai., 2008), the present data points to the strong effect of OT A on mitochondrial 
function, which may in tum induce immunotoxicity. The immune system may respond earlier 
to OT A than it does to other organs. Altered immune function may result in an increased 
incidence of disease or cancer, which may be linked to the various effects produced by OT A, 
since endogenous defence mechanisms will be impaired. 
6.4 CONCLUSION 
The Annexin-V-FLUOS assay revealed that the number of apoptotic lymphocytes was 
significantly higher in the Day IOTA-only treated rat group, compared to the control for the 
same duration. When considering other treatments, however, no significant differences in 
lymphocyte apoptosis were observed. Results acquired from the JC-1 assay showed that the 
percentage of lymphocyte mitochondrial depolarisation significantly increased in the 
S. frutescens rat group after 1 day and in the OTA-only and co-treatment rat groups after 7 
days. Furthermore, OT A and S. frutescens together resulted in a synergistic increase in 
lymphocyte mitochondrial depolarisation. 
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CHAPTER 7 
EXAMINATION OF RAT KIDNEYS 
BY FLUORESCENCE MICROSCOPY 
7.1 INTRODUCTION 
The examination of tissue by microscopy is important for assessing the toxicity of chemicals. 
By delving into the structure of the cell, the morphological features associated with 
cytotoxicity can be further understood. There are several morphological alterations that can 
occur during and after cellular damage. These can be viewed by use of special optical 
techniques, such as phase-contrast microscopy, differential interference contrast microscopy 
and fluorescence microscopy (Becker et ai., 2003). 
7.1.1 Fluorescence Microscopy 
In the fluorescence microscope, light coming from a mercury lamp passes through a specific 
excitation filter that removes all wavelengths, except those wavelengths absorbed by the dye 
(Herman, 1998). In response to light absorption, the dye fluoresces by releasing longer 
wavelengths. The wavelength of fluorescence needs to be removed from that of the exciting 
light in order to allow adequate separation of the two wavelengths (Ormerod, 2000). 
Therefore, the fluorescent light leaving the specimen passes through a second filter, called the 
barrier filter (Herman, 1998), which eliminates all wavelengths except the fluorescent light. 
Contrast is attained after passage of light through the barrier filter, and therefore the specimen 
stained by a fluorescent dye is visualised against a dark background (Herman, 1998; Wilson 
and Walker, 2005). Certain biological molecules, such as chlorophyll, may emit fluorescence 
naturally; this is called autofluorescence (Herman, 1998). Other molecules in cells require 
fluorescent probes to detect various aspects of that cell. Fluorescence is a sensitive method of 
detection. Fluorochromes can also be used to label other probes, such as antibodies, so that 
the localisation of particular antigens can be achieved. 
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7.1.2 Hoechst Stain 
Hoechst stains are part of a family of fluorescent stains that is used to identify DNA 
(Ormerod, 2000). It is membrane permeant and binds specifically to the adenine-thymine 
base pairs in double-stranded DNA. Since the dye is bound to DNA, it is therefore used to 
visualise nuclei. The dye emits blue/green fluorescent light at an emission spectrum of 
around 461 nm, at the nuclear area. During apoptosis the nucleus of the cell is made up of 
highly condensed chromatin. After viewing slides by fluorescence microscopy, the distinct 
morphological changes of the nucleus chromatin can be observed (Willingham, 1999). 
Furthermore, the nuclei of apoptotic cells may develop a horseshoe shaped appearance when 
stained or may appear as complete, intensely fluorescent spherical beads. 
7.1.3 Immunohistochemistry 
The detection of antigens in tissue sections is referred to as immunohistochemistry (IHC). An 
antigen is any foreign molecule that is recognised by an antibody. In this study, 
immunohistochemistry was used for the quantification ofthe toxicant (OTA) in kidney tissue. 
There are two types of methods that can be used for detection, i.e., direct and indirect methods 
(Ramos-Vara, 2005) (Fig. 7.1). 
The direct methods use a primary antibody that is directly tagged to a fluorochrome. In 
contrast, the technique used in indirect methods involves an initial incubation with an 
unlabelled primary antibody, which recognises and then binds to the antigen of interest. This 
is followed by a subsequent incubation with a fluorescent or enzyme-labelled secondary 
antibody, which is then visualised by light microscopy (Ramos-Vara, 2005). The utilisation 
of a secondary antibody which is conjugated to a fluorochrome makes the detection of the 
antigen-primary antibody-secondary antibody complex easier. The indirect technique is more 
commonly used and has several advantages, such as greater sensitivity and that stronger 
signals are obtained (Wilson and Walker, 2005). Therefore, the indirect method was applied 
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Figure 7.1: Diagrammatic representation of direct and indirect immunohistochemical 
methods (Wilson and Walker, 2005). 
Usually, an antigen retrieval step is carried out before antigen detection, since some antigenic 
sites might have become masked during tissue fixation. Antigen retrieval serves to break the 
methylene bridges (formed by fixation) and cross-link proteins, which makes the primary 
antibody inaccessible to the antigen (Ramos-Vara, 2005). There are two methods of antigen 
retrieval: enzymatic or heat-mediated. Enzymatic antigen retrieval is much more gentle than 
heat-mediated, however, it does takes longer and may sometimes damage the morphology of 
the section (Ramos-Vara, 2005). 
The aim of the study reported in this section was to identify the morphological aspects 
associated with apoptosis (chromatin condensation) and to immunolocalise OTA in kidney 
sections of male Wistar rats. In addition, kidneys from rats treated with S. frutescens were 
examined for possible cyto-protective effects. 
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7.2 MATERIALS AND METHODS 
7.2.1 Materials 
Finefix solution was purchased from Milestone (Italy); Ethanol, Xylene, Paraffin wax, 
Tri-sodium citrate (dehydrate) and PBS tablets were purchased from Merck (S.A); 
Poly-L-Iysine, Fluorescent-labelled secondary antibody and DPX mountant were purchased 
from Capital Laboratory Supplies (S.A.); Hoechst 33342 and Bovine Serum Albumin (BSA) 
were purchased from Roche Diagnostics (S.A.); Anti-OT A was purchased from Abcam; 
Triton X-IOO was acquired from Biorad (S.A.); and slides and coverslips were acquired from 
Shalom Laboratories (S.A.). All other reagents and chemicals were obtained from Merck 
(S.A). 
7.2.2 Methods 
7.2.2.1 Specimen Preparation 
After immersion in Finefix solution (Chapter 3), samples were removed from the solution and 
then dehydrated through a series of increased alcohol concentration: 50% ethanol, 70%, 90% 
and two changes in 100% ethanol (1 hr each). The time period for specimen dehydration 
varies with size, thus large specimens were dehydrated for a longer period of time. When the 
kidneys were immersed in these solutions, gentle agitation was required to allow equal 
dehydration on all sides. The kidney tissue was then placed in a 1: 1 solution of xylene and 
ethanol, followed by a clearing step in 100% xylene. Ethanol steps were followed with 
xylene to remove alcohol from tissue sections. Xylene is toxic and all steps that required 
xylene usage were carried out in a fume hood. 
Finally, paraffin wax was heated in a water bath from a solid state to a liquid state. There 
were two changes in the paraffin wax, which allows infiltration into tissue. Paraffin wax 
(liquid at 60°C) is used since it serves as a good medium, one that provides excellent 
morphological detail and resolution. After infiltration, tissue was placed in moulds and 
covered with paraffin wax. The wax-containing moulds were set at room temperature. 
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Thereafter, paraffin blocks were sectioned at 3)..tm using a microtome. Sections were placed 
in a water bath (50°C) in order to remove any wrinkles or creases that may have formed on 
the section. Sections were picked up on poly-L-Iysine coated slides. This type of coated slide 
is used since it allows the section to adhere onto the slide. Once the sections were picked up 
on the slides, slides were dried on a hot plate (60°C) to remove any water that may have been 
trapped underneath the section. 
7.2.2.2 Preparation Before Staining 
Before any staining procedure was performed, sections were de-paraffinised and rehydrated. 
Incomplete removal of paraffin could result in poor staining of the section. Therefore, sections 
were rinsed in two changes of 100% xylene. Sections were also re-hydrated by rinsing in two 
changes each of 100% xylene and 100% ethanol (1: 1) and one rinse in 95% and 70% ethanol 
(5 min each). The xylene steps were followed by ethanol to remove xylene from tissue 
sections. Subsequently, sections were washed with dH20. To prevent the sections from 
drying out, sections were placed in dH20 water until ready to be used. 
7.2.2.3 Hoechst Staining 
Tissue sections were initially washed in PBS (PH 7) and then stained with a Img/ml solution 
of Hoechst 33342 and incubated (15 min) in the dark. Following this, the slides were once 
again washed with PBS and sections were then dehydrated. Dehydration was carried out by 
dipping slides in increasing concentrations of ethanol (50%, 70%, 90% and 100%) and then 
rinsing in xylene. Xylene can be toxic, therefore, steps involving xylene were carried out 
under a fume hood. Sections were then mounted with DPX mountant; the coverslip was 
placed over the section and then viewed with an Olympus IXSI inverted research microscope 
which is equipped with the Olympus DP12 microscope digital camera system. Slides were 
viewed using filter 2, with excitation and barrier wavelengths of 330nm-385nm and 420nm. 
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7.2.2.4 Immunohistochemistry 
7.2.2.4a Heat-Mediated Antigen Retrieval 
The antigen retrieval solution, sodium citrate buffer pH 6 (Appendix CI), was allowed to boil 
and, at this point, slides were placed in the antigen solution, and then placed into the 
microwave (15 min). Citrate-based solutions enhance the staining intensity of the antibody. 
Sufficient solution was used so that the slides were completely covered, which in turn allows 
evaporation to occur during boiling. Slides were then removed from this solution and washed 
twice with PBS and 0.025% Triton X-IOO (PBST) solution (5 min each). 
7.2.2.4b Antibody Optimisation 
After antigen retrieval, sections were covered with a blocking solution, 2% BSA 
(Appendix C2) (2 hrs, RT). Slides were then drained for a few seconds on tissue paper and 
carefully wiped around the sections. Care was taken to avoid drying of sections, since this 
may cause non-specific antibody binding and high background staining. Tissue sections were 
placed in a humidified container containing wet tissue paper, which was placed at the bottom 
of the container. Thereafter, the primary antibody Anti-OT A (1001lI) was added to cover the 
section. Four dilutions were used, 1 :50, 1: 1 00, I :200, I :500 (Appendix C4), to determine 
optimal antibody concentration. Sections were incubated overnight with the primary antibody 
(4°C). Overnight incubation ensured maximum binding of the antibody. 
The following day, sections were rinsed twice using PBST solution (5 min each) with gentle 
agitation. A fluorescent-labelled secondary antibody (1 :500) (Appendix C5) was then applied 
over the section (1 hr, RT). After I hr the slides were rinsed in PBST (3 rinses 5 min each). 
Slides were then coverslipped and viewed. A primary antibody dilution of I : I 00 was chosen. 
7.2.2.4c Antibody Incubation and Image Analysis 
The same procedure (as in 7.2.2.4b) was carried out for all of the kidney sections, using a 
primary antibody dilution of I : 1 00. Images were viewed using an Olympus IXSI microscope. 
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7.3 RESULTS AND DISCUSSION 
Apoptosis results in chromatin condensation. The Hoechst stain, a DNA intercalator, helps to 
detect and identify chromatin condensation. Analysis of Hoechst-stained images revealed 
kidney tissue with intense fluorescence in the glomerular region in all ofthe samples (Fig. 7.2 
and Fig. 7.3). 
The control (Fig. 7.2) differed from other groups in that no fluorescence was observed outside 
of the glomerulus. On Day 1, a number of fluorescent nuclei were seen in the glomerular 
region. However, after 7 days, fluorescent staining decreased. It is known that cells may 
undergo proliferation in response to stress. Thus, the intense staining of the nuclei in the 
glomerular area may be indicative of mitosis. This can be deduced, since the morphological 
aspects of mitosis and apoptosis, such as chromatin condensation and dissolution of nuclear 
membranes, are similar. The decreased nuclear fluorescent staining at Day 7 may be due to 
mitosis. It is possible that after 7 days the rats may have adapted to the control treatment 
conditions. 
The rat kidneys that were treated by S. frutescens alone (Fig. 7.2) showed nuclear 
fluorescence that was more intense than that of the control. This staining pattern (Fig. 7.2) 
depicts nuclei with condensed chromatin. Sutherlandia frutescens is a known inducer of 
apoptosis. L-canavanine (present in S. frutescens) has the ability to induce apoptosis. 
Furthermore, S. frutescens causes cell death in cultured cells, which was previously shown by 
morphological aberrations, phosphatidylserine externalisation, chromatin condensation and 
nuclear fragmentation (Chinkwo, 2005). Condensation of nuclei with the breakdown of 
chromatin is characteristic of apoptosis. 
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Figure 7.2: Kidney sections stained with Hoechst 33342: 1) Control Day 1 (40x); 2) Control 
Day 7 (40x); 3) S. frutescens-only Day 1 (40x); 4) S. frutescens-only Day 7 (40x). 
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Fluorescence intensity was higher in the OT A-only treatment groups on Day 7 compared with 
Day 1 (Fig. 7.3). There were numerous condensed nuclei in the glomeruli of the Day 7 
OTA-only treated kidney sections. Kidney sections from the co-treatment rat group showed 
that fluorescent staining was higher after the 7 -day treatment. The staining pattern in the 
combination groups (Days 1 and 7) did not differ significantly from the OT A-only treatments. 
The images of the kidney sections suggest that OTA may induce renal cell injury (Fig. 7.3). 
Renal cell injury was previously noted by Domijan et ai. (2004) and Schwerdt et ai. (2007). 
In acute toxicity studies, OT A-induced cell death was reported in vivo in rat renal tubules and 
in mice embryos and livers (Petrik et ai. , 2003). Petrik et ai. (2003) found that OT A induced 
apoptosis in both proximal and distal tubule cells in the kidneys of male Wi star rats 
(treated for 10 - 60 days), whilst the present study showed apoptosis to occur only in the 
glomerular area (treated for 1 and 7 days) . Although these images are strongly suggestive of 
apoptotic processes, the PBMC assays for apoptosis was not significant (Chapter 6). 
It is also known that after a toxic insult some cells suffer injury and may undergo 
programmed cell death. In the case of OT A, the glomerulus may be the site where cellular 
damage is initiated. Cells present in the glomeruli, such as glomerular visceral epithelial cells 
(podocytes), maintain the structure and function of the glomerular basement membrane. 
These cells aid the filtration process by providing a permeability barrier. Thus, persistent 
glomerular apoptosis may decrease the filtration capacity. And also, defects in the glomerular 
wall structure can thus lead to proteinuria (Ming-Fang Hseih et ai., 2004). Furthermore, 
apoptosis in glomerular cells is the cause of many glomerular diseases and could be one of the 
reasons behind OT A-induced renal toxicity. 
The kidney is a prime organ in which intense oxidative processes can take place and this may 
lead to the production ofROS. In addition to glomerular cells, polymorphonuclear leukocytes 
and monocytes are potential sources of ROS within the glomerulus. Furthermore, OT A may 
induce oxidative damage through the production of ROS or lipid peroxidation (Schaaf et ai. , 
2002; Petrik et ai. , 2003). Reactive oxygen species are common initiators of apoptosis, which 
may account for the intense staining pattern (Fig. 7.3). The glomerulus is the first site of 
76 
exposure to toxins in the kidney. Considering that apoptosis was detected in the glomerulus, 
it is possible that OTA renal toxicity may begin with injury to the glomerular area. 
Figure 7.3: Photomicrographs illustrating kidney sections stained with Hoechst 33342: 
5) OTA-only Day 1 (20x); 6) OTA-only Day 7 (40x); 7) OTA and S. frutescens Day 1 (20x); 
8) OTA and S.frutescens Day 7 (20x). 
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The distribution of an antigen in tissues provides an accurate indication of cytotoxicity. In 
this case, anti-OT A was used to identify the location and distribution of OT A in the kidneys 
(Fig. 7.4 and Fig. 7.5). 
From the immunostained images, intense fluorescence was observed in the glomerulus of both 
OT A and co-treated rats at Days 1 and 7 respectively (Fig. 7.5). The glomerulus was the only 
site at which OT A was detected. This could be due to the increased binding of OT A to 
albumin. Glomerular filtration does not permit movement of albumin into the ultrafiltrate. 
Blood passes through the glomerulus and in this area albumin is restricted from passing into 
the proximal tubule; it exits the glomerulus via the efferent arteriole and rejoins the main 
bloodstream via the renal vein. If a large portion of the OT A that enters the body is bound to 
albumin, then it should be difficult for the toxin to be filtered by the glomerulus. Albumin 
binding may delay OT A elimination by preventing the transfer . from blood to the renal cells. 
Hence, OT A was immunolocalised in the glomerular area only, due to the high levels of 
albumin. 
The glomerulus is the first site in the kidney to be exposed to a toxicant, thus OT A was 
present in this region. The glomerulus provides a barrier against the trans glomerular passage 
of macromolecules, and thus only small molecules are freely filtered. The filtration of anionic 
molecules tends to be restricted as compared with that of neutral or cationic molecules of the 
same size (Schnellmann, 2003). Toxicants that neutralise or reduce the number of fixed 
anionic charges in the glomerulus will impair the charge or size selective properties in that 
region (Smart and Hodgson, 2008). This results in the excretion of polyanionic and/or high 
molecular weight proteins. Subsequently, this may be a reason for the presence of OT A in the 
glomerular cells. 
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Figure 7.4: Illustration of kidney sections incubated with Anti-OTA: 1) Control Day 1 (20x); 
2) Control Day 7 (20x); 3) S. frutescens-only Day 1 (20x); 4) S. frutescens-only Day 7 (20x). 
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Figure 7.5: Photomicrographs showing kidney sections incubated with Anti-OTA: 5) OTA-
only Day 1 (20x); 6) OTA-only Day 7 (40x); 7) OTA and S.frutescens Day 1 (20x); 8) OTA 
and S. frutescens Day 7 (20x). 
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The co-treatment with S. frutescens did not decrease OT A detection in the glomerular area 
(Fig. 7.5). Since OT A preferentially binds to albumin, it seems that S. frutescens had little or 
no effect on inhibition of OT A binding to albumin. Therefore the albumin-bound OT A would 
recirculate until dissociated. Subsequently, it may be important to displace OT A from 
albumin, thus increasing OT A elimination. 
Other studies have detected OT A in tubular regions of the nephron (Schwerdt et at., 1996; 
Dahlmann et al., 1998). The organic anion transporter (OAT) family is important in the 
uptake of anions and may be important in OT A secretion into the tubular regions. However, 
it is believed that OTA may cause alterations to the OAT, which subsequently delays the 
blood-to-Iumen transport of OTA and thus reduces elimination from the body 
(Sauvant et at. , 1998). In addition, by disrupting the OAT, the elimination of other anionic 
xenobiotics will also be reduced, which may in turn further increase toxicity in the body. 
Furthermore, if OT A is unbound and freely available then only can the toxin pass through the 
OAT. Also, it is believed that excretion of OTA may occur by a similar mechanism as pAH, 
which relies on a-ketoglutarate (Groves et at. , 1998). If the concentration of a-ketoglutarate 
is decreased then the OATs may not function optimally. When the concentration of 
a-ketoglutarate in the kidney decreases, then the a-ketoglutarate produced in the blood will 
be transported to the kidney. Therefore, OT A-induced changes in blood a-ketoglutarate may 
in turn lead to renal injury. This means that immunotoxicity may play a crucial role in 
OT A-induced renal cell damage. 
Furthermore, the kidneys are the only organ where highly protein-bound drugs are unbound 
and traverse the tubular cells (De Broe and Roch-Ramel, 1998). Thus, this could also account 
for the presence of OT A in tubular regions in other studies (Schwerdt et at., 1996; Dahlmann 
et at. , 1998). If the rats had been treated for a longer period of time, OT A may have been 
detected in the tubules. 
The occurrence of OT A III tissues is dependent on the animal species used, the dose 
administered, the route of toxin exposure, and the health status of the animals 
(Ringot et al. , 2006). When animals are treated by i.p injection, the toxin of interest is rapidly 
absorbed because of the rich blood supply. Since, in the present study, rats were treated with 
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OT A by i.p injection, it is possible that a large amount of OT A was bound to albumin. 
Subsequently, this may have hindered any increase in OT A in the renal tubules. 
It has been suggested that OT A decreases renal blood flow and the glomerular filtration rate 
(Gekle and Silbernagl, 1996) and that the long-term effects of OTA are usually associated 
with damage to the glomeruli. This may result in an accumulation of the toxin. Thus the 
presence of OT A in the glomerular region, together with apoptosis in this area, may be 
responsible for glomerular damage and glomerular or renal disease at large. 
7.4 CONCLUSION 
Ochratoxin A treatment resulted in the condensation of chromatin in the glomerulus. This 
was noticed after Day 1 and Day 7, but the staining was more intense by Day 7. This is in 
concurrence with the fact that renal injury due to OT A increases after extended periods of 
time. Furthermore, S. frutescens did not alleviate the effect on chromatin condensation and 
the intensity was not changed. Using immunohistochemistry, OTA was localised in the 
glomerular region. The medicinal plant did not reduce the occurrence of OT A in the 
glomerulus. Chromatin condensation is an indication of apoptosis and therefore renal cell 
injury may occur as a result of glomerular disruption. 
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CHAPTER 8 
THE EFFECTS OF OCHRATOXIN A ON 
PROTEIN EXPRESSION IN RAT TISSUE 
8.1 INTRODUCTION 
Electrophoresis is the migration of a charged particle under the influence of an electric field. 
Most biological compounds possess ionisable groups and at any given pH exist in solution as 
either cations or anions (Wilson and Walker, 2005). Thus, under the influence of an electric 
field, charged biological compounds, such as proteins, migrate either to the cathode or to the 
anode. When voltage is applied, molecules with different charges separate as a result of their 
different electrophoretic mobility. Electrophoretic mobility is the ratio of the velocity of the 
ion to the field strength (Wilson and Walker, 2005). Frictional force may also retard the 
movement of a charged molecule. The frictional force is determined by the shape and 
hydrodynamic size of the molecule, the pore size of the medium in which electrophoresis is 
taking place and the viscosity of the buffer (Wilson and Walker, 2005). Sodium 
dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot use this 
principle to separate and transfer proteins from an acrylamide gel onto a polyvinylidene 
fluoride (PVDF) membrane, respectively. 
8.1.1 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is used for 
analysing protein mixtures qualitatively and was first described by Laemmli (1970). Initially, 
proteins are standardised, denatured and then loaded onto an acrylamide stacking gel where 
the proteins are separated according to size in a resolving gel. Proteins of a high molecular 
weight will be found towards to the top of the gel and those of a low molecular weight will be 
found near the bottom. SDS-P AGE is an important application that is used to analyse protein 
purification and to determine the relative molecular mass of proteins. 
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8.1.2 Western Blot 
Immunochemical techniques make use of antibody technology (Fig. 8.1) and provide 
powerful tools for toxicological analyses. Such tools include, assessing the effects of a 
toxicant on intracellular protein localisation, as well as determining the effects of a toxicant 
on protein levels (Smart and Hodgson, 2008). 
Proteins are firstly separated by SDS-PAGE, and then transferred onto a PVDF membrane 
(Fig. 8.1). The proteins that are transferred onto the membrane are a replica of the pattern of 
protein separation on the gel. Subsequently, the blot is incubated in a protein solution to 
prevent non specific binding and thereafter incubated with the relevant primary and secondary 
antibodies. The secondary antibody is appropriately labelled so that the antigen-antibody 
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Figure 8.1: Diagrammatic representation of a Western blot procedure(C - control, 
T - treated) (Smart and Hodgson, 2008). 
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The aim was to detennine the protein expression in the kidney tissue of male Wistar rats after 
OT A treatment. 
8.2 MATERIALS AND METHODS 
8.2.1 Materials 
Tris, Sodium chloride (NaCl), Sodium dodecyl sulphate (SDS), Tetramethylenediamine 
(TEMED), Glycerol, Glycine, Potassium chloride (KCl) , Tween 20, Dithiothreitol (DTT), 
Dipotassium ethylenediaminetetraacetic acid (K2EDTA), Potassium dihydrogen phosphate 
(KH2P04), Sucrose, Methanol, Fonnaldehyde, Silver nitrate, Citric acid, Acetic acid, 
Ammonium hydroxide, Sodium hydroxide (NaOH), PBS tablets and Eppendorfs were 
purchased from Merck (S.A); Bicinchoninic acid (BCA), Copper sulphate (Cu(II)S04), 
B-mercaptoethanol, Bromophenol blue and Rabbit Anti-mouse-HRP secondary antibody were 
obtained from Capital Laboratory Supplies (S.A.); Ammonium persulphate (APS), Non-fat 
dry milk and Immun-StarTM Chemiluminescent Detection Kit were obtained from Bio-rad 
(S.A.); Bovine serum albumin (BSA) was purchased from Roche (S.A.); Anti-OTA was 
obtained from Abcam and 96 well microtiter plates were purchased from the Scientific Group 
(S.A.). All other chemicals were purchased from Merck (S.A.) 
8.2.2 Methods 
8.2.2.1 Protein Isolation 
Homogenising buffer (3ml) (Appendix Dl) was added to sliced kidney (approximately 0.2g) 
tissue and the tissue was then homogenised. Thereafter, samples were centrifuged 
(3 min, 1 OOOrpm, 4°C), to remove any cellular debris. The pellet was discarded. An aliquot 
of the supernatant was retained as the crude fraction and another aliquot was subjected to 
differential centrifugation to yield mitochondrial, nuclear and cytoplasmic fractions. For the 
nuclear fraction, the supernatant was centrifuged (10 min, 3 500rpm, 4°C) and the pellet 
(nuclear fraction) obtained was re-suspended in storage buffer (Appendix D2) and stored for 
further use. The resultant supernatant was re-centrifuged (10 min, 10 OOOrpm, 4°C), the pellet 
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was re-suspended in storage buffer and constituted the mitochondrial fraction whilst the 
supernatant was retained as the cytoplasmic fraction. 
8.2.2.2 Protein Quantification: Bicinchoninic Acid (BCA) Assay 
Initially a Img/ml BSA stock solution was prepared and this solution was diluted accordingly 
to make standard concentrations (Appendix D3). 
Each sample (20JlI) was added to a 96 well microtiter plate in duplicate. BCA working 
solution was prepared by adding BCA (198 JlI/well) to Cu(II)S04 (4Jlllwell). The working 
solution (200JlI) was dispensed into each well including the standards. Samples were then 
incubated (30 min, 37°C). Peptide bonds in the protein reduce copper (Cu2+) ions from the 
copper sulphate (Cu(II)S04). The amount of Cu2+ that is reduced is proportional to the 
amount of protein present in the sample. Two molecules of BCA chelate each Cu + ion 
forming a purple coloured product that strongly absorbs light at a wavelength of 562nm. 
Thus, the optical density was measured at 562nm on a Quant ELISA plate reader 
(Analytical Diagnostic products (S.A.)). 
Next, a standard curve was drawn to determine protein concentration and samples were then 
standardised to Img/ml (Appendix D3). 
8.2.2.3 SDS-PAGE 
Initially, a 10% resolving gel (Appendix E 1) was prepared and was allowed to set 
(30-60 min). Thereafter, a 6% stacking gel (Appendix E2) was prepared. A comb was 
inserted and the stacking gel was poured in, in order to form sample loading wells and was 
then allowed to set (30 min). 
The standardised proteins were diluted in sample buffer (IOOJll) (Appendix E3) in a 1:1 ratio, 
and then heated (5 min, 95°C). Sample buffer contains SDS, which denatures and uncoils the 
polypeptide chains and a thiol reducing agent, mercaptoethanol. Bromophenol blue, a tracker 
dye, also present in the sample buffer, was used to determine how far the sample moved in the 
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resolving gel. Glycerol was also incorporated into the sample buffer to add density to the 
sample, thus ensuring that the sample sunk to the bottom of the well in the stacking gel. 
Finally, the denatured sample (25~1) was added to each well, according to each treatment. 
Running buffer (Appendix E4) was then added to the electrophoresis tank and samples were 
electrophoresed (l hr, 150V). On completion of the electrophoretic run, gels were Silver 
stained (Appendix E5) and thereafter the relative mobility (Rt) was determined. The Rf was 
calculated by measuring the distance of the molecular weight marker from the top to the 
bottom dye front. Then, the distance of each band was determined from the top to the 
position of band, and this was divided by the molecular weight marker distance. A standard 
curve of Log molecular weight and Rf was used to determine the molecular weight of the 
proteins. 
8.2.2.4 Western Blot 
After protein separation by SDS-PAGE, the acrylamide gel and a blotting (PVDF) membrane 
were sandwiched between fibre pads and filter paper, in a cassette. The cassette was then 
placed in the electrophoresis tank and completely covered with chilled transfer buffer 
(PH 8.3) (Appendix E6). A cooling unit was also placed in the tank to ensure that the transfer 
buffer remained cool during transfer. In addition, a stir bar was also placed in the tank to help 
maintain an even buffer temperature and ion distribution in the tank. The tank transfer 
apparatus (tank containing tank buffer and gel sandwich) was placed on a stirrer and the 
maximum speed was used. Thus, proteins from serum and kidney tissue were 
electrophoretically transferred onto a PVDF membrane by wet transfer (1 hr, 350mA). After 
transfer, the gel was Silver stained (Appendix E5) to ensure that the transfer onto the 
membrane was successful. 
Thereafter, the PVDF membrane was immersed in 5% non-fat dry milk (Appendix E7) and 
placed on an orbital shaker for 1 hr, then incubated overnight (4°C). The purpose of non-fat 
dry milk is to block all remaining non-specific sites. 
87 
Upon removal from the 5 % non-fat dry milk solution, the membrane was then incubated with 
the primary antibody (Anti-OTA), diluted in a 1:5 000 ratio (50 min, RT). Following this 
incubation period, the membrane was then washed vigorously with TTBS (Tween-Tris 
buffered saline) (3 washes, 5 min each) (Appendix E8). Thereafter the membrane was 
incubated with a rabbit Anti-mouse-HRP secondary antibody (1: 10 000) (45 min, RT). An 
orbital shaker was used for primary and secondary incubation so that the entire membrane 
was exposed to the antibodies. After secondary antibody incubation, the membrane was again 
washed with TTBS (3 washes, 5 min each). It is important to note that after each step a clean 
container was used to avoid carry-over from one step to the next and each rinse was carried 
out on an orbital shaker. 
The Immun-Star™ HRP Chemiluminescent detection kit was utilised and in the presence of 
hydrogen peroxide, HRP (horse radish peroxidase) catalyses the oxidation of luminol, which 
acts as the substrate. Luminol and peroxide buffer solutions, provided in the kit, were mixed 
in a 1: 1 ratio and the membrane was then incubated in this solution (3-5 min). The Bio-rad 
Gel Doc XRS imaging system was used for detection and images were viewed using the 
Bio-rad Quantity 4.4.1 analysis software. 
8.2.3 Statistical Analysis 
Band intensity was measured using the Image J analysis software and statistical significance 
between treatments was determined using One-Way Analysis of Variance (AN OVA) and 
Tukey Kramer Multiple Comparisons test, on GraphPad Instat v3.06 (GraphPad Software, 
San Diego, CA). A probability value (P) of less than 0.05 (p<0.05) was considered 
statistically significant. 
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8.3 RESUL TS AND DISCUSSION 
Crude, mitochondrial, nuclear and cytoplasmic fractions were each loaded into separate gels. 
Each fraction consisted of the following treatments: control-Day 1 (Lane 1), control-Day 7 
(Lane 2), S. frutescens-only-Day 1 (Lane 3), S. frutescens-only-Day 7 (Lane 4), OTA-only-
Day 1 (Lane 5), OTA-only-Day 7 (Lane 6), OTA and S. frutescens-Day 1 (Lane 7), OT A and 
S. frutescens-Day 7 (Lane 8) (Fig. 8.2 and Fig. 8.3). 
Comparisons between each fraction revealed a protein, approximately 150kDa, in the 
mitochondrial and cytoplasmic fractions only. Furthermore, a 63.1kDa protein was detected 
in the mitochondrial fraction. However, this protein was more prominent in the cytoplasmic 
fraction. The mitochondrial and cytoplasmic fractions both showed the presence of a 26kDa 
protein. A 38.9kDa protein was detected in the mitochondrial, nuclear and cytoplasmic 
fractions. It is possible that proteins of a similar molecular weight were observed since 
differential centrifugation was used to separate proteins. This may have resulted in some 
protein residues being either left behind in a previous fraction or carried over into the next 
fraction. 
In the mitochondrial fraction (Fig. 8.2), whilst the 150kDa protein was present in control 
samples, protein expression was decreased in OT A-only treated rats at Day 1 and 7 and 
co-treated rats at Day 1 and 7. When compared to the controls OTA-only and combination 
treatment resulted in a decrease in expression of the 63.1kDa and 26kDa proteins after the 
Day 1 and 7 regimes. Also, the expression of a 13.8kDa protein, although present in control 
groups (Lane 1 - Lane 4), was absent in other treatment groups. It has been suggested that 
OT A treatment results in mitochondrial disruptions, and that this may occur as an early event 
in toxicity (Aleo et a!., 1991; Bouaziz et a!., 2008). It is possible that this may be related to 
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Figure 8.2: SDS-PAGE gels (Silver stained) showing crude (A) and mitochondrial (B) 
fractions. (Mw) Molecular weight marker; (1) Control Day 1; (2) Control Day 7; 
(3) 8. frutescens-only Day 1; (4) 8. frutescens-only Day 7; (5) OTA-only Day 1; 
(6) OTA-only Day 7; (7) OTA and 8.frutescens Day 1; (8) OTA and 8.frutescens Day 7. 
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Furthennore, it is possible that protein synthesis may be compromised by OT A by interacting 
with phenyl-handling proteins at post-transcriptional level, such as phenylalanyl-tRNA-
synthase (Schwerdt et ai., 1999; Stoev, 1998; Simon et ai. , 1996; Marin-Kuan et ai., 2006). 
This could alter the production of tyrosine from phenylalanine. 
In the cytoplasmic fraction (Fig. 8.3) a decrease in expression of a 12.6kDa and a 10.7kDa 
protein was detected. The expression ofthe 63.lkDa and 38.9kDa proteins was prominent in 
all treatments. Nuclear fractions showed that the expression of a 208.9kDa protein was more 
prominent in the S. frutescens group on Day 1 and combination group rats on Day 7. There 
was a decrease in expression of a 12.3kDa protein in the nuclear fraction. Furthennore, the 
43.7kDa, 38.9kDa and 26.3kDa proteins were highly expressed in all treatments of the nuclear 
fraction. 
In the study by Maaroufi et ai. (1999), it was observed that a higher concentration of OT A 
was found in the blood than in the kidney, for all doses tested. Other studies have shown that 
there was an inhibition of various proteins as a result of OTA toxicity (Schilter et ai., 2005). 
Ochratoxin A may not have caused interruptions in protein synthesis, due to the short time 
(1 day or 7 days) period in the body and dose given to rats and therefore drastic changes were 
not observed. Also, since a large portion of OT A is bound to albumin, glomerular filtration is 
restricted. The albumin-bound OT A therefore returns into circulation. Furthennore, the 
images presented in Chapter 7 showed that OT A was immunolocalised in the glomerular area 
and not in the tubules. This demonstrates that the binding of OT A to albumin limits the 
transfer of OT A from the blood to renal cells. Subsequently, this may result in decreased 
effects on protein expression in kidney tissue since, only the unbound fonn may be available 
for elimination by the kidneys. 
Usually, the inhibition of protein synthesis results in the decrease of cell growth or 
proliferation. Other studies have demonstrated that OT A caused a down regulation of genes 
that are important for protein synthesis, thereby decreasing protein synthesis 
(Marin-Kuan et ai. , 2006). It is possible that OT A may not directly inhibit protein synthesis, 
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Figure 8.3: SDS-PAGE gels (Silver stained) showing cytoplasmic (A) and nuclear (B) 
fractions. (Mw) Molecular weight marker; (1) Control Day 1; (2) Control Day 7; 
(3) S. frutescens-only Day 1; (4) S. frutescens-only Day 7; (5) OTA-only Day 1; 
(6) OTA-only Day 7; (7) OTA and S.frutescens Day 1; (8) OTA and S.frutescens Day 7. 
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Figure 8.2 and Figure 8.3 also illustrate that there was no difference in protein expression 
after the S. frutescens treatment compared to the controls. Also, protein expression of the 
combination treatment did not vary from the OT A-only groups. This suggests that 
S. frutescens may not alleviate the observed effects on OTA-induced protein expression. 
Previous studies used radiolabeled OT A to determine its distribution in serum and kidney 
(Stojkovic et aI. , 1984; Kane et al. , 1986). However, this method may have disadvantages, 
such that not all of the radioactivity detected may be due to OT A, but may also result from 
degradation products such as phenylalanine or OT A-a (Schwerdt et aI., 1996). By using 
Western blot, the distribution of OT A can be determined with the aid of specific antibodies. 
Analysis of the Western blot revealed that OTA bound to albumin and a high molecular 
weight (120kDa) serum protein (Fig. 8.4 and Fig. 8.5). It was observed that OTA bound to 
serum proteins even after the Day 1 regime, thus supporting the view that OTA rapidly binds 
to serum proteins once exposed to them. The binding of OT A to proteins may increase the 
susceptibility to various diseases. 
Ochratoxin A also bound to rat serum-derived proteins even in the co-treatment groups, 
Group 7 and Group 8 (Fig. 8.4 and Fig. 8.5). Although other studies have shown that OTA 
could bind to other lower molecular weight proteins (Schwerdt et al., 1999), this was not 
observed in the present study. Furthermore, the binding of OT A to kidney proteins was not 
detected in this study. 
Schwerdt et al. (1999) demonstrated the ability of OT A to bind to various proteins in the 
kidney tissue. However, in the above study, a method that involved the coupling of OTA to 
HRP was employed to detect OT A-protein binding. A nitrocellulose membrane was then 
incubated overnight with the OTA-HRP conjugate. In contrast, the present study used an 
OT A antibody (Anti-OT A) to test for the presence of OT A bound proteins in rat kidneys in 
vivo. Hence, differences were found regarding the lack of OTA binding in rat kidneys in the 
present study. Schwerdt et al. (1999) also found that OT A bound to serum proteins, 40kDa 
and 27kDa in molecular weights, which was not found in the present study. However, the 
present study revealed that OTA may also bind to a high molecular weight (l20kDa) serum 
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protein. Binding to this high molecular weight protein, further ensures that OT A remains in 
the body for a longer period of time. It is possible that this high molecular weight protein 
may represent one of the globulins present in plasma. 
The combination treatment of OT A and S. frutescens also showed the binding of OT A to 
serum proteins (Fig. 8.4 and Fig. 8.5). In addition, the combination treatment demonstrated 
that S. frutescens did not result in the binding of OT A to other serum proteins. The binding of 
OT A to serum albumin is an important mechanism by which the toxin may have a longer 
chronic exposure time. If this binding is inhibited, then OT A can be eliminated from the body 
more efficiently. 
After the analysis of the band intensities, it was revealed that there were significant 
differences between the band intensities of each treatment. With regard to the 120kDa protein 
band intensity (Fig. 8.4), it was observed that the band intensity of the 7-day OTA-only group 
was higher than that of the OTA-only Day 1 regime (p<0.01). This means that a higher 
concentration of OT A was bound to this high molecular weight protein after a long dosage 
period (OTA-only 7 days). This in agreement with other studies that suggest OTA induces 
severe toxicity after prolonged exposure (Sauvant et aI. , 1998; Schwerdt et at., 2007). 
Furthermore, a comparison between the OT A-only (Day 1) and the combination treatments 
(Fig. 8.4), showed that the combination treatment (Day 1) had a significantly higher band 
intensity for the same period of time (p<0.001). This suggests that even when treated with 
S. frutescens, the binding of OT A to the 120kDa serum protein was increased. However, after 
the 7-day combination regime the band intensity decreased significantly (p<0.01). Thus, 
although S. frutescens may not have completely inhibited the binding of OTA to this protein 
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Figure 8.4: Analysis of the band intensities after the detection of Ochratoxin A bound to 
120kDa serum protein. Data represent mean ±SEM. **p<O.OI, ***p<O.OOl. 
Considering the 65kDa protein, there were no significant differences observed between the 
band intensities of the OT A-only Day 1 and 7 regimes (Fig. 8.5). In addition, a comparison 
between the band intensities of the Day 1 OT A-only and combination treatments showed no 
significant difference (Fig. 8.5). However, there was a significant decrease in the band 
intensity ofthe combination treatment after 7 days (p<O.OI) (Fig. 8.5). 
The results displayed in Figure 8.4 and Figure 8.5 indicate that S. frutescens may decrease the 
binding efficiency of OT A to serum proteins. Ochratoxin A is known to preferentially bind to 
serum albumin (Hagelberg et ai., 1989), thus, decreasing this binding may result in the 
elimination of OTA from the body, since the unbound fonn may be filtered by the 
glomerulus. Sutheriandia frutescens contains L-ARG and L-CA V. It is possible that OTA 
may have bound to L-ARG or L-CA V instead of binding to albumin, and thus lower band 
intensities were noticed after the 7 -day combination treatment. Immunoprecipitation is one of 
the techniques that could be employed to show whether OT A was bound to L-ARG or L-CA V 
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instead of albumin. It is possible that with the repeated treatment of S. frutescens, the binding 
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Figure 8.5: Analysis of the band intensities after the detection of Ochratoxin A bound to 
serum albumin. Data represent mean ±SEM. **p<0.01. 
According to Mantle (2008) and Dahlmann et al. (1998), OTA can be reabsorbed along 
various sites of the nephron. Ochratoxin A is an organic anion at physiological pH and it is 
suggested that organic anion transporters playa significant role in the movement of unbound 
OT A into the tubules. The differences in transporters may influence OT A accumulation in 
cells (O'Brien and Dietrich, 2005). Also, high blood and tissue levels of OTA may be 
observed when there are repeated applications (Zepnik et at., 2003). Thus in the present 
study, it is probable that the given time period did not allow for OT A accumulation in the 
target organ, the kidney. 
Furthermore, it is necessary to consider that the majority of OT A may have been bound to 
albumin, following the injection into the peritoneal cavity. Due to the binding of OTA to 
albumin, the fraction of unbound toxin in the body is low. Therefore, the bound toxin 
recirculates in the body until dissociation, since only the unbound free toxin would be 
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available for glomerular filtration. It is the dissociation constant for albumin-OT A complexes 
that is important for glomerular filtration (Mantle, 2008). 
The fact that OTA binds to albumin also means that the amount of free (usable) albumin is 
decreased. In addition, modifications in albumin may prevent degradation (Nicholson et ai., 
2000). Thus, the catabolism of albumin may be reduced when bound to OT A. As a result, 
there would be a decrease in free amino acids, which are the final breakdown products of 
albumin in cells and plasma. Furthermore, the binding of OT A to albumin may subsequently 
compromise the immune cells. From the data presented in Chapter 6, it is possible that the 
increase in lymphocytes with depolarised mitochondria may be due to the albumin-OT A 
conjugate that was formed. 
In accordance with the study by Maaroufi et ai. (1999), it is possible that a higher 
concentration of OT A may have been present in blood rather than the kidney. 
8.4 CONCLUSION 
The results show that, due to OT A treatment, the expression of some proteins was decreased, 
in particular that of the mitochondria. This effect was not inhibited by the medicinal plant 
S.frutescens. Analysis by Western blot did not detect the binding ofOTA to kidney proteins 
and this may have been attributed to the time period of treatment. However, the results 
indicate that OTA bound to two rat serum proteins (albumin and 120kDa) in the OTA-only 
(Day 1 and 7) and the OT A and S. frutescens combination treatment groups (Day 1 and 7). 
The measurement of the 120kDa protein band intensities showed that the combination group 
produced the highest band intensity (120kDa) after the Day 1 regime. However, the band 
intensity (120kDa) was reduced after the 7-day combination regime. Regarding serum 
albumin, there was a significant decrease in band intensity after a 7 -day OT A and 
S. frutescens combination treatment. From this study, it is evident that with a repeated dose of 




The current data highlights mitochondrial dysfunction due to OTA toxicity. This was 
supported by the drastic changes in PBMC viability as noted by the MTT assay, which is 
dependent on metabolic activity and the lymphocyte mitochondrial depolarisation after OT A 
treatment. A significant increase in DNA damage was observed, which may be related to the 
increase in apoptosis that was noticed after short-term OTA treatment. In the present study 
kidney mitochondrial protein expression was decreased after OT A treatment. This may be 
related to the OT A-induced mitochondrial dysfunctions. 
Condensed chromatin, indicative of apoptosis, was found in the glomerulus of OTA-treated 
rats. In addition, OT A was also immunolocalised in the glomerular region, even when treated 
with a combination of S.frutescens. Furthermore, Western blot showed the presence ofOTA 
bound to serum albumin and a 120kDa serum protein. Glomerular filtration does not allow 
the movement of large proteins into the ultrafiltrate and only the unbound form is filtered and 
eliminated from the body. Taken together, OT A detection in the glomerulus as well as 
apoptosis in this area suggests that OT A may cause glomerular damage. 
Sutherlandia frutescens proved to have a protective role against OTA-induced alterations in 
PBMC viability. While S. frutescens did not alleviate the OT A-induced increase in 
lymphocyte mitochondrial depolarisation, a synergistic increase was however observed. This 
response may have occurred as both OT A and S. frutescens affect mitochondrial function. 
The results also suggest that S. frutescens decreased the binding of OT A to serum proteins 
after repeated treatments. It is possible that OT A may have bound to the positively charged 
L-ARG or L-CAV, present in S. frutescens , instead of albumin, which may have resulted in 
the observed decreased OTA-albumin binding. If the OTA-protein complexes are decreased, 
then OTA may be eliminated from the body faster, thus decreasing toxicity. 
Finally, the use of S. frutescens as a possible antidote for OTA-induced toxicity may prove 
beneficial after repeated doses. It is evident from the present study that alterations in immune 
98 
function may result in renal damage. The immune system may respond earlier to OT A than 
other organs. And, altered immune functions may result in the increased incidence of disease, 
which may be linked to the various effects produced by OT A. There are several studies 
regarding OT A-induced toxicity in the kidney, thus the in vivo data here presented on 
OTA-induced immunotoxicity is pertinent for future research. 
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1. Preparation of Ochratoxin A 
5mglml stock solution was made. From this stock, 100fll was used for Ikg rats = 0.5mg. So, 
for 300g rats 30fll this is = 0.15mg. 
Therefore 15 doses = 30fll x 15 = 450fll 
To make 3ml, 450fll of toxin was added to 2 550fll of vehicle. 
Vehicle was 70% H20 and 30% EtOH. 
Therefore: 
2 550 x 70% = I 785fll dH20 
2550 x 30% = 765fll EtOH 
2. Preparation of Sutherlandia frutescens stock solution 
Ten 300mg (total mass = 3g) Sutherlandia frutescens tablets were crushed with a pestle and 
mortar and subjected to polar solvent extraction of active ingredients in 13.5ml vehicle 
(EtOH:dH20;70:30) (4 hr, RT). Following extraction, particular matter was pelleted by 
centrifugation (5 min, 400xg, RT). 
The stock S.frutescens solution = -300mgl13.5ml = 222.2mglml 
The stock was further diluted 10-fold = 22.22mglml 
The treatment dose of I mg S. frutescens (Sf)/kg rat body weight (bw) was required therefore: 







Therefore 0.05ml (50fll) SF /kg bw 
Average rat body weight = O.3kg (300g). Therefore 50fll x 0.3kg = 15fll Sfl300g bw. As 15fll 
was an insufficient volume to inject directly into the rat, this dose was further increased to 
200fll (Sf masslbw ratio remains the same). 50fll of lO-fold diluted Sutherlandia stock 
(with 150fll vehicle) was injected into each rat at Day I and Day 7 dosing. 
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Appendix B 
Calculations for SCGE 
1. LMPA 
1 % LMP A - I g of LMP A was dissolved in 100ml PBS 
0.5% LMPA - 0.5g ofLMPA was dissolved in 100ml PBS 
2. 250ml Lysing Solution 





2.5 = 0.25 




mass = nxM = 0.625 x 58.44 = 36.53g for 250ml 





0.1 = 0.25 




mass = nxM = 0.025 x 292.94 = 7.32g for 250ml 
• t % 1M Tris (6.06g in 50ml dH20, pH 10) 
• 1% Triton x-tOO 
• 10% DMSO 
NaCl (36.53g), EDTA (7.32g), 1M Tris (2.5ml), Triton X-100 (2.5ml) and DMSO (25ml) 
were added to dH20 , to make a total volume of 250mllysing solution. 
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3. 1 litre Electrophoresis buffer (PH 13) 










mass = nxM = 0.3 x 40 = 12g 





0.001 = 1 




mass = nxM = 0.001 x 372 = 0.372g 
Thus NaOH (12g) and Na2EDTA (0.37g) were dissolved in 800ml of dH20, the pH was 
checked (PH 13) and volume was then adjusted to 1 OOOml with dH20. 










mass = nxM = 0.4 x 121.14 = 48.46g 
Tris (48.46g) was added to 800ml of dH20 , pH was adjusted and volume was topped up to 




1. Sodium citrate buffer (PH 6.0) for Antigen retrieval 
Tri-sodium citrate (2.94g) was dissolved in 800ml of distilled water. The pH was adjusted to 
6.0, and then brought to a final volume of 1 OOOml and 0.5ml of Tween 20 was added. 
2. 2% BSA 
2g ofBSA was dissolved in 100mi of PBS 
3. 1 % Bovine serum albumin (BSA) 
Ig ofBSA was dissolved in 100ml of PBS 
4. Dilutions for primary antibody optimisation 
1/50 - 2JlI of primary antibody diluted in 98JlI of 1 % BSA 
11100 - 2JlI of primary antibody was diluted in 198JlI of 1 % BSA 
1/200 - 2JlI of primary antibody was diluted in 398JlI of 1 % BSA 
1/500 - 2JlI of primary antibody was diluted in 998JlI of 1 % BSA 
5. Dilution of secondary antibody 
1/500 - 2JlI of secondary antibody (Goat anti-mouse IgG) in 998JlI of 1 % BSA 
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AppendixD 
Protein Isolation and Standardisation 
1. Isolation/Homogenising Buffer (lOOml) 





0.05 = 0.1 




mass = nxM = 0.005 x 121.14 = 0.61g 





0.001 = OJ 




mass = nxM = 0.0001 x 404.47 = 0.040g 
• ImMDTT 
Taken from 1M DTT stock solution 
CIVI = C2V2 
1M x VI = 0.001 x 100ml = O.lml 
Thus Tris (0.61g), K2EDTA (0.04g), DTT (O.lml) and a protease cocktail, was added to 60ml 
dH20. The pH was adjusted to 7.4 and was then brought to a volume of 100ml in dH20. 
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2. Storage Buffer (PH 7.4) (SOml) 





0.1 = 0.05 




mass = nxM = 0.005 x 136 = 0.68g 





0.000 5 = 0.05 




mass = nxM = 0.000 025 x 404.4 = 0.010 19 
• ImMDTT 
Taken from 1M DTT stock solution 
CIVI = C2V2 
1M x VI = 0.001 x 50ml = 0.005ml 











mass = nxM = 0.012 5 x 342.3 = 4.28g 
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KH2P04 (0.68g), K2EDTA (O.Olg), DTT (0.005 ml) and Sucrose (4.28g) was added together 
in 30ml dH20; adjusted to pH 7.4, and then brought to a volume of 50ml with dH20. 
3. BSA Standards 



















A standard curve was drawn to determine protein concentration. The linear equation 
(y = mx + c) obtained from the standard curve was used to determine protein concentration, 




1. 10% resolving gel 
dH20 (4 lOOlll), Acrylamide bis (3 300lll), 1.5M Tris (2 500lll), 10% SDS (l001l1), 10% APS 
(501l1) and TEMED (51l1) were added together. 
• I.5M Tris (PH 8.8) for 10% resolving gel 
27.23g ofTris was dissolved in 100ml dH20 , corrected to pH 8.8, and then adjusted volume 
to 150ml. 
2. 6% Stacking gel 
dH20 (54 0001l1), Acrylamide bis (2 0001l1), 0.5M Tris (2 500IlI), 10% SDS (lOOIlI), 10% 
APS (501l1) and TEMED (1 o Ill) were added together. 
• 0.5M Tris (PH 6.8) for 6% Stacking gel 
Tris (6g) was dissolved in 80ml dH20 , corrected to pH 6.8, then adjusted volume to 100ml. 
• 10% Ammonium persulphate (APS) 
Dissolved 25mg APS in 250111 dH20 
3. Sample buffer (Final volume - 9.5ml) 
dH20 (3.55ml), 0.5M Tris-HCI pH 6.8 (1.25ml), Glycerol (2.5ml), 10% (w/v) SDS (2.0 ml), 
0.5% (w/v) bromophenol blue (0.2ml). 
50111 mercaptoethanol was added to 950111 sample reducing buffer, which was then mixed 
with isolated proteins (l : 1). 
4. Electrode Running buffer (PH 8.3) 
Tris base (30.3g), Glycine (144g) and SDS (lOg) were dissolved in 1 OOOml of dH20, which 
was a lOx buffer. To obtain a Ix electrode running buffer, 50ml of the lOx buffer was diluted 
in 450ml dH20. 
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5. Silver Stain 
Gels were soaked in a 7% acetic acid solution for 7 min. Gels were then soaked twice in SO% 
methanol (20 min each). Thereafter, solution A, silver nitrate, was made by adding 0.8g of 
silver nitrate to 4ml of water. After soaking gels in methanol, gels were rinsed twice in water 
(10 min each). S min before the end of the final water rinse solution B was made. Solution B 
consisted of 21ml of water, 2S0~1 of 30% sodium hydroxide (NaOH) and 1.4ml of 
ammonium hydroxide. In order to make the staining solution, solution A was added to 
solution B in a drop-wise manner, whilst stirring, thereafter, 76ml of water was added. Gels 
were then soaked in the staining solution for about 4-S min. Thereafter, gels were rinsed in 
two changes of water (S min each). The developing solution was made using 200ml of water, 
Iml of 1 % citric acid and 100~1 of 37% formaldehyde. After rinsing, gels were soaked in 
developing solution between 1-4 min. Finally, 7% acetic acid was added to the gels to stop 
development; this was followed by three changes of water. 
Western Blot 
6. Transfer buffer 
Mix together 2SmM Tris (3.03g), 192mM Glycine (14.4g) and 20% v/v methanol (200ml) in 
SOOml of dH20 (PH 8.3). Bring volume up to 11 with dH20 and chill until ready to use. 
7. 5% non-fat dry milk to block the membrane 
3 g non-fat dry milk was dissolved in 60ml of TTBS 
8. TBS: NaCI (8g), KCI (O.2g) and Tris (3g) were added together in 800ml dH20 , adjusted 
to pH 7.S and brought to a volume of 11 with dH20 . 
• TTBS - add O.Sml Tween 20 to 11itre TBS 
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